1	Cellular and molecular heterogeneities and signatures, and pathological
2	trajectories of fatal COVID-19 lungs defined by spatial single-cell transcriptome
3	analysis
4	
5	Short title: Spatial single-cell transcriptome analysis of COVID-19 lungs
6	
7	Arun Das ^{1,2} †, Wen Meng ^{1,3} †, Zhentao Liu ^{1,4} , Md Musaddaqul Hasib ^{1,2} , Hugh
8	Galloway ^{1,4} , Suzane Ramos da Silva ^{1,3} , Luping Chen ^{1,3} , Gabriel L Sica ⁵ , Alberto Paniz-
9	Mondolfi ⁶ , Clare Bryce ⁶ , Zachary Grimes ⁶ , Emilia Mia Sordillo ⁶ , Carlos Cordon-Cardo ⁶ ,
10	Karla Paniagua Rivera ⁷ , Mario Flores ⁷ , Yu-Chiao Chiu ^{2,8} , Yufei Huang ^{1,2,4*} , and Shou-
11	Jiang Gao ^{1,3*}
12	
13	¹ Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh
14	School of Medicine, Pittsburgh, PA, USA
15	² Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA,
16	USA
17	³ Department of Microbiology and Molecular Genetics, University of Pittsburgh School of
18	Medicine, Pittsburgh, PA, USA
19	⁴ Department of Electrical and Computer Engineering, Swanson School of Engineering,
20	University of Pittsburgh, Pittsburgh, PA, USA
21	⁵ Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA,
22	USA

- ⁶Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of
- 24 Medicine at Mount Sinai, New York, New York, USA
- 25 ⁷Department of Electrical and Computer Engineering, KLESSE School of Engineering
- 26 and Integrated Design, University of Texas at San Antonio, San Antonio, TX, USA
- 27 ⁸Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh
- 28 School of Medicine, Pittsburgh, PA, USA
- 29
- 30 +These authors contributed equally to this work.
- 31 *Corresponding authors. Emails: <u>yuh119@pitt.edu</u>; <u>gaos8@upmc.edu</u>

32 Abstract

33 Despite intensive studies during the last 3 years, the pathology and underlying 34 molecular mechanism of coronavirus disease 2019 (COVID-19) remain poorly defined. 35 Here, we examined postmortem COVID-19 lung tissues by spatial single-cell 36 transcriptome analysis (SSCTA). We identified 18 major parenchymal and immune cell 37 types, all of which are infected by SARS-CoV-2. Compared to the non-COVID-19 38 control, COVID-19 lungs have reduced alveolar cells (ACs), and increased innate and 39 adaptive immune cells. Additionally, 19 differentially expressed genes in both infected 40 and uninfected cells across the tissues mirror the altered cellular compositions. Spatial 41 analysis of local infection rates revealed regions with high infection rates that are 42 correlated with high cell densities (HIHD). The HIHD regions express high levels of 43 SARS-CoV-2 entry-related factors including ACE2, FURIN, TMPRSS2, and NRP1, and 44 co-localized with organizing pneumonia (OP) and lymphocytic and immune infiltration 45 that have increased ACs and fibroblasts but decreased vascular endothelial cells and 46 epithelial cells, echoing the tissue damage and wound healing processes. Sparse non-47 negative matrix factorization (SNMF) analysis of neighborhood cell type composition 48 (NCTC) features identified 7 signatures that capture structure and immune niches in 49 COVID-19 tissues. Trajectory inference based on immune niche signatures defined two 50 pathological routes. Trajectory A progresses with primarily increased NK cells and 51 granulocytes, likely reflecting the complication of microbial infections. Trajectory B is 52 marked by increased HIHD and OP, possibly accounting for the increased immune 53 infiltration. The OP regions are marked by high numbers of fibroblasts expressing 54 extremely high levels of COL1A1 and COL1A2. Examination of single-cell RNA-seq

55 data (scRNA-seq) from COVID-19 lung tissues and idiopathic pulmonary fibrosis (IPF)

56 identified similar cell populations primarily consisting of myofibroblasts.

57 Immunofluorescence staining revealed the activation of IL6-STAT3 and TGF-β-

58 SMAD2/3 pathways in these cells, which likely mediate the upregulation of COL1A1 and

59 COL1A2, and excessive fibrosis in the lung tissues. Together, this study provides an

60 SSCTA atlas of cellular and molecular signatures of fatal COVID-19 lungs, revealing the

61 complex spatial cellular heterogeneity, organization, and interactions that characterized

62 the COVID-19 lung pathology.

63

64 Key words: SSCTA, spatial single-cell transcriptome analysis; COVID-19, coronavirus

disease 2019; SARS-CoV-2; SNMF, sparse non-negative matrix factorization analysis;

66 NCTC, neighborhood cell type composition analysis; trajectory inference; organizing

67 pneumonia; fibrosis; IL6-STAT3; TGF-β-SMAD2/3

68 Introduction

69 Multiple single-cell RNA-seq (scRNA-seq) analyses of coronavirus disease 2019 70 (COVID-19) patients with different severities have improved our understanding of 71 cellular diversity associated with infection and provided important molecular insights into 72 the host immune response [1-5]. Despite intensive studies in the last 3 years, the 73 pathology and underlying molecular mechanism of COVID-19 remain unclear. Severe 74 COVID-19 is often accompanied by diffuse alveolar damage (DAD) that presents 75 complex pathological manifestations and is heterogeneous within infected tissues and 76 across patients [6]. The dissociation of tissue localization of cells in scRNA-seq has 77 become a bottleneck to decoding the pathology features at the molecular and cellular 78 levels and failed to reveal the immune signatures of the microenvironment for severe 79 COVID-19.

80 Spatial single-cell transcriptome analysis (SSCTA) promises to reveal the 81 molecular basis of cellular heterogeneity, organization, and interactions in tissues and 82 organs [7, 8]. However, analysis of these complex datasets including defining the spatial 83 cellular organizations, immune microenvironment patterns, cell-cell interactions, and 84 molecular signatures associated with disease pathophysiology remains a daunting task. 85 Here, we utilized SSCTA to examine postmortem lung tissues from 5 cases with 86 severe COVID-19 and one case without COVID-19. From 10,414,863 detected 87 transcripts of cellular 221 genes from six tissues, we identified 1,719,459 cells that were 88 mapped to 18 major parenchymal and immune cell types, all of which are infected by 89 SARS-CoV-2. We further identified the spatial cellular and molecular signatures that 90 define the patterns of SARS-CoV-2 infection, structural and pathological presentations,

91 and associated immune microenvironments, which project the trajectories of disease

92 progression. Together, this study provides an atlas of cellular and molecular signatures

93 of fatal COVID-19 lungs and reveals the complex spatial cellular heterogeneity,

94 organization, and interactions that characterize COVID-19 lung pathology.

95

96 Results

97 Spatial single-cell transcriptome analysis, cell segmentation, cell typing, and
98 spatial mapping of cells.

99 Postmortem lung tissues from five COVID-19 autopsies and one postmortem 100 case without COVID-19 were subjected to SSCTA (Fig. 1A). All five COVID-19 cases 101 contracted SARS-CoV-2 in the first wave of the pandemic and had underlying 102 conditions [9], including hypertension (cases 1-3), HIV infection and asthma (case 2), 103 and Parkinson's and chronic kidney diseases (cases 4 and 5). Hematoxylin and eosin 104 (H&E) stains revealed various degrees of diffuse alveolar diseases (DAD), pulmonary 105 thromboembolism, and lymphocytic infiltration in all cases (Fig. S1). Tissues 1 and 2 (1-106 2C and 2-1A) had prominent organizing pneumonia (OP) or organizing diffuse alveolar 107 damage while edema, hyaline membrane, and fibrin clot or microthrombi were 108 prominent in tissues 3, 4, and 5 (3-1A, 4-3B and 5-3B). We designed probes for 109 detecting the SARS-CoV-2 genome and 221 cellular genes covering markers of 110 common lung parenchymal and immune cells, and immune and inflammatory genes 111 induced by viral infections (Table S1). Following hybridization and gene decoding by in-112 situ sequencing, we stained the tissues with 4',6-diamidino-2-phenylindole (DAPI) (Fig. 113 S2) to facilitate cell segmentation (Fig. S2).

114 A workflow was developed to analyze the SSCTA data (Fig. 1B). We detected 115 869,453 to 3,424.675 reads in the six lung tissues for a total of 10,414.863 reads (Table 116 S2 and Fig. S3A). Using the Baysor algorithm [10], we segmented ~89%-95% of reads 117 into cells based on DAPI staining and the spatial distribution of reads (Fig. S4). We 118 identified 186,659 to 470,294 cells for each sample for a total of 1,719,459 cells in these 119 tissues (Table S2 and Fig. S3B). Over 99% of the cells harbored at least 5-15 reads 120 (Fig. S5). We further filtered the cells deemed low quality (see Methods) and retained a 121 total of 779,137 cells for the subsequent analyses.

122 We summarized the reads for each gene and normalized the gene reads of 123 segmented cells using scTransform [11]. We assigned cell types to 70-84% of the 124 segmented cells based on the expressions of cell type-specific markers (Table S1) and 125 identified a total of 18 cell types including 11 types of parenchymal cells and 7 types of 126 immune cells in all six tissues (Fig. 1C and S6). We used Uniform Manifold 127 Approximation and Projection (UMAP) to visualize the relationship of gene expressions 128 of individual cells associated with different cell types in all tissues (Fig. 1D and S7). 129 There were negligible batch differences as cells from different samples mixed well in 130 individual cell clusters (Fig. 1D and S7). We noticed separated clusters for major 131 parenchymal cells including alveolar cells (ACs) and fibroblasts. By contrast, immune 132 cells were grouped together and mixed with vascular endothelial cells (VECs) in several 133 clusters (Fig. 1D). The poor separation of immune cell types was largely due to highly 134 expressed immunoglobulin kappa light chain (IGKC) and cathepsin L (CTSL) in these 135 cell types (Fig. S8).

136 We then mapped the individual cells to their spatial locations in the tissues (Fig. 137 S9) and performed the neighborhood cell type composition (NCTC) analysis by 138 computing a vector of 18 cell-type percentages in the neighborhood of individual cells. 139 NCTC reveals spatial variations of the local cell type composition and informs local 140 interplays among cell types. In agreement with the observed pathology that showed 141 DAD in all COVID-19 tissues (Fig. S1), NCTC uncovered disorganized distributions of 142 various cell types, especially the major parenchymal cells such as ACs, VECs, and 143 fibroblasts (Fig. 1E, S1, and S10-S14). In contrast, organized structures and orderly 144 distributions of these cell types were observed in the non-COVID-19 tissue (PBC-PR) 145 (Fig. 1E, S1, and S15). Examination of regions with blood vessels revealed the lining of 146 VECs along the vessels together with other vessel-associated cells including ACs, 147 fibroblasts, and smooth muscle cells (SMCs) (Fig. 1E and S16). Furthermore, we 148 observed abundant infiltrating immune cells including macrophage and monocytes 149 (MMs), natural killer (NK) cells, and T- and B-cells along regions of blood vessels (Fig. 150 1E and S10-S14). We also observed the expected cell compositions of other structures 151 including bronchiole, capillary, and endothelium (Fig. S17). These results validated the 152 marker-based cell typing approach.

153

SARS-CoV-2 infection alters the cell compositions of major parenchymal cells and induces immune infiltrations.

In agreement with the results of our previous study [9], we found SARS-CoV-2
reads in diverse cell types with infection rates ranging from 0.6% to 5% except that no
infected cell was detected in the small number of erythrocytes (55) identified in tissue 1

159 (Fig. 1D, 1F, S7 and Table S3). Most infected cells were identified as ACs, fibroblasts, 160 VECs, and MMs as they were the major cell types in the COVID-19 tissues (Fig. 1F). 161 Consistent with the tissue pathology, we observed significant alterations in the 162 compositions of different cell types in COVID-19 tissues compared to the non-COVID-163 19 tissue (Fig. 1E and 1F). Among the parenchymal cells, there were reduced numbers 164 of ACs from 44.08% to 12.81-28.23% and SMCs from 5.22% to 1.72-3.05%, and increased numbers of epithelial cells (ECs) from 2.08% to 2.40-8.42%, ionocytes from 165 166 0.22% to 0.41-1.36% and basal cells from 0.25% to 0.31-1.58%, suggesting their likely 167 involvements in COVID-19 lung pathology (Fig. 1E, 1F, and Table S3). Furthermore, we 168 observed increases in cell numbers of most types of the identified immune cells in 169 COVID-19 tissues (Fig. 1E, 1F, and Table S3). In particular, there were increased 170 inflammatory cells including MMs from 9.4% to 17.51-21.37% and NK cells from 1.00% 171 to 2.32-9.19%, and adaptive immune cells including T cells from 2.40% to 4.34-6.81% 172 and B cells from 1.91% to 2.70-10.51%, which were consistent with the reported 173 inflammatory and cellular immune response following SARS-CoV-2 infection [12]. 174 However, these changes were more subtle for some cell types in tissue 1, which had 175 the least infected cells and mildest pathological manifestations with the best integrity of 176 parenchymal cells among all COVID-19 tissues (Fig. 1E, 1F, S1, and S10). 177

SARS-CoV-2 infection induces global differential gene expressions that marked
 pathological damages and inflammation with spatial cellular features.

180 We examined the differential gene expression between COVID-19 and non-181 COVID-19 lung tissues, and identified 9 upregulated and 10 downregulated genes,

182 respectively (Fig. 2A, first panel). Comparison of SARS-CoV-2-infected cells in COVID-183 19 tissues with all cells in the non-COVID-19 tissue confirmed the differential 184 expressions in 16 of these 19 genes (Fig. 2A, second panel). Interestingly, differential 185 gene expressions were also observed in 18 of these 19 genes between uninfected cells 186 in COVID-19 tissues and all cells in the non-COVID-19 tissue (Fig. 2A, third panel). In 187 contrast, there were only 3 differentially expressed genes between SARS-CoV-2-188 infected and -uninfected cells in the COVID-19 tissues (Fig. 2A, fourth panel). These 189 results indicated that there were strong indirect effects such as those mediated by 190 cytokines and complement activation induced by SARS-CoV-2 infection that likely 191 contributed to the dysregulated gene expressions and pathology in COVID-19 lung 192 tissues. Thus, we focused on comparing COVID-19 tissues with the non-COVID-19 193 tissue in subsequent analyses of dysregulated genes.

194 The expressions of the 19 dysregulated genes in different cell types and their 195 tissue distributions had significant variations suggesting their complex involvements in 196 different aspects of SARS-CoV-2 infection and COVID-19 lung pathology (Fig. 2B, 2C, 197 S8, and S18-S23). We determined the contributions of individual cell types to the 198 expressions of these genes across all the tissues (Fig. 2D). Of the 19 genes, 10 of them 199 were cell markers (Table S1). All 6 parenchymal cell markers including SFTPC, 200 SFTPA1, and advanced glycosylation end product (AGE) receptor (AGER) for ACs, 201 INMT for fibroblasts, smooth muscle actin alpha 2 (ACTA2) for SMCs, and claudin 5 202 (CLDN5) for VECs were downregulated, and mainly expressed in their respective cell 203 types (Fig. 2A, first panel, 2C, 2D, S8 and S18-S23), of which ACs and SMCs had 204 decreased cell numbers in COVID-19 tissues (Fig. 1E, 1F and S7). Both SFTPC and

205 SFTPA1 are implicated in lung homeostasis and functions, and their mutations and 206 dysregulation are associated with pulmonary fibrosis [13-15]. Additionally, SFTPA1, a 207 C-type lectin, which binds to specific carbohydrate moieties on lipids and the surface of 208 microorganisms, is essential in the defense against respiratory pathogens [16-18] while 209 the pulmonary-associated surfactant protein C encoded by SFTPC is a marker for 210 COVID-19 patients with high viral loads [19]. AGER, predominantly expressed in ACs 211 (Fig. 2C), is a multiligand receptor interacting with AGE and other molecules implicated 212 in lung homeostasis, development and inflammation, and certain diseases such as 213 diabetes and Alzheimer's disease, and regulates diverse pathways including MyD88-214 dependent, nuclear receptors, TNF- α , ERK1/2 and p38 MAPK, and p53/TP53 pathways 215 [20-23]. Following interaction with S100A12, AGER triggers the activation of 216 mononuclear phagocytes, lymphocytes, and endothelium by generating key pro-217 inflammatory mediators [24]. Indeed, AGER-related pathways are activated by SARS-218 CoV-2 infection and are implicated in the COVID-19 lung pathology [25, 26]. ACTA2 219 encodes a smooth-muscle actin involved in lung functions including cell motility, tissue 220 structure and integrity, and intercellular signaling [27]. Dysregulation of ACTA2 is linked 221 to a variety of vascular diseases as well as multisystemic smooth muscle dysfunction 222 syndrome [28, 29]. CLDN5 is an integral membrane protein and component of tight 223 junction strands regulating the integrity of epithelial or endothelial cell sheets, and 224 immune cell transmigration [30-32]. SARS-CoV-2 infection suppressed CLDN5 225 expression contributing to the disruption of respiratory vascular barriers [33]. Thus, 226 downregulations of parenchymal cell markers including SFTPC, SFTPA1 and AGER in

ACs, ACTA2 in SMCs, and CLDN5 in VECs might be involved in SARS-CoV-2 infectionand COVID-19 lung pathology (Fig. 2D).

229 Several other downregulated genes including caveolin 1 (CAV1) and alpha-2-230 macroglobulin (A2M) are implicated in numerous lung functions (Fig. 2A). CAV1, a 231 component of caveolae involved in multiple pathways such as integrins-mediated and 232 Ras-ERK signaling, is essential for lung functions and during the host response to 233 infections [34, 35]. A2M is an inhibitor of broad spectrum of proteases including trypsin, 234 thrombin, and collagenase [36, 37]. It disrupts inflammatory cascades by inhibiting 235 inflammatory cytokines, is implicated in Alzheimer's disease, and regulates extracellular 236 matrix organization and platelet cytosolic Ca2+ [36, 37]. CAV1 and A2M were 237 downregulated and mainly expressed by ACs, fibroblasts, VECs, and MMs (Fig. 2A, first 238 panel, 2D, S8, and S18-S23), of which ACs and fibroblasts had decreased while MMs 239 had increased cell numbers in COVID-19 tissues (Fig. 1F). 240 Three upregulated immune marker genes including complement component C1q, 241 A chain (C1QA) and B chain (C1QB), and neural cell adhesion molecule 1 (NCAM1) are 242 involved in innate immune response and inflammation (Fig. 2A, first panel) [38, 39]. 243 C1QA and C1QB were predominantly expressed in MMs (Fig. 2D, S8 and S18-S23). 244 SARS-CoV-2 infection induced robust complement activation, contributing to tissue 245 damage and COVID-19 lung pathology [40-42]. Both cathepsin L (CTSL) and granzyme 246 K (GZMK) could be involved in complement activation [43, 44]. CTSL was induced after 247 SARS-CoV-2 infection and enhanced SARS-CoV-2 infection [45] while GZMK, a serine 248 protease from the cytoplasmic granules of cytotoxic lymphocytes (CTL) and NK cells 249 that recognize and lyse specific target cells [46], could limit the spread of SARS-Co-V-2.

250 Both CTSL and GZMK were upregulated and mainly expressed by ACs, fibroblasts, 251 MMs, and VECs while CTSL exhibited a comparable expression level but with 252 extremely high levels in localized regions in COVID-19 tissues (Fig. 2A, 2B, 2C, 2D, S8 253 and S18-S23). NCAM1, the marker of NK cells, is a member of the immunoglobulin 254 superfamily involved in cell-to-cell interactions as well as cell-matrix interactions [47]. 255 The upregulations of C1QA, C1QB, CTSL, GZMK, and NCAM1 were consistent with the 256 increased numbers of MMs and NK cells in COVID-19 tissues (Fig. 1F, S8, and S18-257 S23). Thus, increased infiltrations of MMs and NK cells were likely involved in COVID-258 19 lung complement activation and inflammation.

259 Two immune-modulating cytokines were upregulated including colony-stimulating 260 factor 3 (CSF3), a member of the IL-6 superfamily of cytokines that controls the 261 production, differentiation, and function of granulocytes involved in the innate immune 262 response [48, 49], and inducible T cell costimulator ligand (ICOSLG or B7-H2) involved 263 in positive regulation of interleukin-4 production and CD28 signaling in T-helper cells 264 [50, 51]. The major cells that expressed CSF3 and its receptor CSF3R, as well as 265 ICOSLG and its receptor ICOS, were ACs, fibroblasts, VECs, and MMs (Fig. 2D). 266 Numerous other upregulated genes in COVID-19 tissues are involved in 267 inflammatory and immune responses (Fig. 2A). Leukocyte-specific transcript 1 (LST1), a 268 myeloid leukocyte-specific transmembrane adaptor protein recruiting protein tyrosine 269 phosphatases SHP-1 and SHP-2 to the plasma membrane, inhibits the proliferation of 270 lymphocytes, and its expression is enhanced by lipopolysaccharide (LPS), interferon-271 gamma (IFN- γ) and bacteria [52, 53]. Immunoglobulin kappa light chain (IGKC) is 272 essential for antibody production but is also expressed in non-lymphoid cells [54-56].

Both LST1 and IGKC were mainly expressed in ACs, fibroblasts, VECs and MMs (Fig.
2B-E, S8 and S18-S23), which might mediate dysregulation of immune cells in COVID19 lung tissues. Finally, fibulin 1 (FBLN1), a secreted glycoprotein incorporated into a
fibrillar extracellular matrix in a calcium-dependent manner and mediates platelet
adhesion via binding fibrinogen [57, 58], was mainly expressed in ACs, fibroblasts,
VECs, and MMs (Fig. 2D).

279 We examined differential gene expressions in cell types that had significant 280 changes in cell numbers (Fig. 1F). Compared to non-COVID-19 tissue, ACs from 281 COVID-19 tissues had 20 differentially expressed genes, of which 14 were identified at 282 the whole tissue level (Fig. 2A, first panel and 2E). The most upregulated genes were 283 LST1, CTSL, IGKC, ICOSLG, C1QB, GZMK, and NCAM1 while the most 284 downregulated genes were SFTPC, A2M, SFTPA1, CLDN5, and CAV1 (Fig. 2E), which 285 likely contribute to the decreased cell numbers in COVID-19 tissues (Fig. 1F). Several 286 differentially expressed genes were also identified in fibroblasts, VECs and ECs (Fig. 287 2E). Among the immune cells, MMs had the most differentially expressed genes 288 including upregulation of C1QB, NCAM1, and IGKC, and downregulation of A2M, CD68, 289 TYROBP and PRG4 (Fig. 2E).

290

Spatial analysis identifies regions with high SARS-CoV-2 infection rates that
match high cell densities, high levels of viral entry-related factors, and localized
pathology.

Even though we did not observe notable global differences in gene expression between infected and uninfected cells within each COVID-19 tissue, the spatial nature

296 of the SSCTA permitted the identification of the local impact of SARS-CoV-2 infection 297 on lung pathology. We performed the local infection rate analysis to examine the spatial 298 distributions of local SARS-CoV-2 infection (Fig. 3A) and identified regions with high 299 and low infection rates in each tissue (Fig 3B; local Moran's I, p-value < 0.05). SARS-300 CoV-2 infects host cells by binding to its entry receptor, angiotensin-converting enzyme 301 2 (ACE2), and subsequent engagement of host proteases and other entry-related 302 factors including FURIN, transmembrane protease, serine 2 (TMPRSS2), and neuropilin 303 1 (NRP1) [59]. We assessed the spatial correlation between high-infection regions and 304 cells expressing transcripts of these viral entry-related proteins. We found a significant 305 correlation between high infection rates and high expressions of ACE2, FURIN, 306 TMPRSS2, and NRP1 (Fig. 3C; bivariate local Moran's I, p-value < 0.05), supporting the 307 essential roles of these cellular proteins in SARS-CoV-2 infection in lung tissues. 308 Previous studies reported increased densities of both parenchymal and immune 309 cells in COVID-19 lung tissues [6]. Here, we observed a positive spatial correlation 310 between cell densities and SARS-CoV-2 infection rates especially in tissues 1-4 (Fig. 311 3D, Table S4), suggesting that increased cell densities might be associated with high 312 infection rates. We segmented regions with high infection rates and high cell densities 313 (HIHD) (Fig. 3E; bivariate local Moran's I, p-value < 0.05). Compared with H&E staining 314 (Fig. S1), we found a close association between HIHD and OP, which was most 315 prominent in tissues 1 and 2, as well as lymphocytic and immune infiltration, which was 316 most severe in tissues 3 and 4 (Fig. 3E). Both are the most common lung pathological 317 manifestations in COVID-19 lungs [12]. Hence, high infection rates might cause 318 persistent damages to the lung tissues, resulting in the infiltration of immune cells, and

increased wound repair and fibrosis [60, 61]. We also observed HIHD areas adjacent to
blood vessels in tissues 1 and 3 (Fig. 3E and S1), which might be due to the homing of
the circulating virus and immune cells in the bloodstream to these sites or that these
cells were more susceptible to SARS-CoV-2 infection [9, 62].

323

Regions with high SARS-CoV-2 infection rates have unique cellular and gene expression features.

326 We next examined cell type compositions of the high and low SARS-CoV-2 327 infection regions. Compared to low-infection regions across the tissues, the 328 compositions in high-infection regions exhibited significant increases in fibroblasts, 329 echoing the observed OP in HIHD areas, and an increase in ACs, possibly due to the 330 proliferation of ACs response to injury repair of alveoli and alveoli capillaries (Fig. 3E 331 and 4A). However, there were decreases in ECs and VECs, which might reflect the 332 damages caused by the infection (Fig. 3E and 4A). These results suggested that high-333 infection regions might suffer more damages. However, except for T cells and 334 granulocytes, the compositions of major immune cell types including MMs between high 335 and low infection regions remained similar (Fig. 4A), suggesting induction of a broad 336 immune infiltration by SARS-CoV-2 infection, as well as the observed broad impact on 337 the tissue-wide gene expression (Fig. 2A).

The patchwork of high infection regions in tissue 1 prompted us to inspect patterns of local cell-type compositions. Interestingly, NCTC analysis showed three clusters in high-infection regions, of which two were distinctly enriched with prominent local compositions of fibroblasts and ACs, respectively (Fig. 4B). Examining their spatial

distributions confirmed a negative *in-situ* correlation between local compositions of
fibroblasts and ACs (-0.6, Pearson correlation), with regions showing high (low)
compositions of fibroblasts accompanied with low (high) compositions of ACs (Fig. 4B
and C). Strikingly, the local regions with high fibroblasts but low ACs were mostly
annotated OP regions (Fig. S1).

347 We next investigated the gene expression patterns in the high- and low-infection 348 regions. Compared with the normal tissue, the high and low infection regions presented 349 highly consistent differential expression patterns as they shared 18 of the 20 350 differentially expressed genes (Fig. 4D), confirming the strong indirect effect of SARS-351 CoV-2 infection (Fig. 2A). One of the two uniquely differentially expressed genes in high 352 infection regions was again cytokine CSF3, which was upregulated in all infected 353 tissues. We, therefore, investigated spatial co-expression of CSF3 and its receptor 354 CSF3R (Fig. 3F) and found that their co-expression patterns also presented spatial 355 correlations in high infection regions (Fig. 3G; bivariate local Moran's I, p-value < 0.05), 356 suggesting that the CSF3-CSF3R axis might modulate the immune response in high-357 infection regions. In contrast to the consistent differentially expressed patterns of both 358 high- and low-infection regions when compared with the normal control, direct 359 comparison between high- and low-infection regions revealed distinct differentially 360 expressed patterns. Particularly, we observed, in high-vs. low-infection regions, 361 upregulation of AC markers SFTPA1 or SFTPA2 in tissues 1, 3, and 5 (Fig. 4E and 2C) 362 and fibroblast markers COL1A1 or COL1A2 in all COVID-19 tissues (Fig. 4E and 4F), 363 despite that SFTPA1 and COL1A2 displayed down-regulation in either high- or low-364 infection regions in COVID-19 tissues when compared to the normal tissue (Fig. 4D).

365 The increased expressions of these AC and fibroblast markers were also consistent 366 with the observed increases in ACs and fibroblasts in high-infection regions in the 367 corresponding tissues (Fig. 4A). Cell type-specific differential expressions further 368 confirmed the upregulation of SFTPA1 or SFTPA2 in ACs, and COL1A2 in fibroblasts in 369 infected tissues (Fig. 4E and S24). However, different cell types exhibited complex 370 differential expression patterns between high vs. low infection regions in individual 371 COVID-19 tissues (Fig. S24), likely due to the distinct COVID-19 pathologies or stages 372 associated with the individual infected tissues.

373

374 Sparse non-negative matrix factorization analysis identifies seven cell

375 composition signatures that recapitulate different healthy and disease statuses.

376 Although different DAD phases can inform COVID-19 severity, they are 377 confounded by many factors including the underlying conditions of the patients as 378 illustrated by our five COVID-19 cases (Fig. S1). Importantly, the complex tissue 379 microenvironments of parenchymal and immune cells associated with different stages of 380 DAD within and across tissues have not been well characterized. Therefore, we 381 determined the extent to which tissue-independent and tissue-specific spatial patterns in 382 spatially resolved cell-type compositions are associated with different DAD stages. For 383 this purpose, we performed the sparse non-negative matrix factorization (SNMF) [63] of 384 the NCTC vectors of all cells in all tissues. SNMF decomposed these NCTC vectors into 385 a sparse linear combination of cell-type composition signatures that define spatial cell-386 type patterns in these tissues. We obtained a factorization of seven NCTC signatures 387 after assessing the compactness and biological meanings of the factorization results for

388 different maximum numbers of factors (Fig. 5). Close examination of cell type 389 compositions of the signatures (Fig. 5A and Table 5) and their spatial prevalence across 390 all tissues (Fig. 5B) defined by the factor loading revealed their associations with normal 391 structures, and broad and tissue-specific infection. Specifically, Signature 1 likely 392 defined the cell type composition of "normal-like lung alveoli" because it has 56.4% 393 ACs, 18.5% VECs, 11.9% fibroblasts, and 5.3% SMs, which were comparable to the 394 percentages of the non-COVID-19 tissue (Fig. 1F and Table S3). Thus, the high-loading 395 regions of Signature 1 in COVID-19 tissues might mark the less damaged regions. 396 Naturally, the non-COVID-19 tissue had a high prevalence of Signature 1 (Fig. 5B and 397 S25). Tissue 1 had the highest prevalence of Signature 1 among all COVID-19 tissues 398 reflecting its least damaged pathology, followed by tissue 4, 3, 2, and 5 (Fig. 5B, S1, 399 and S25). Signature 2 described a composition of 61% ECs, 14% ciliated cells, and 400 10% basal cells. It had sparse but high-intensity loadings in localized regions identified 401 as bronchial tubes (Fig. 5B and S1). In contrast to Signatures 1 and 2 which 402 characterized cell-type compositions of normal structures, Signature 3 captured the 403 "broad immune infiltration" as it contained 28.6% B cells, 22.3% MMs, 17.5% T cells, 404 9.6% granulocytes, and 8.7% ECs (Fig. 5A and Table S5). As expected, it was the least 405 common in the non-COVID-19 tissue (Fig. 5B and S25). Its loading distributions in 406 COVID-19 tissues were consistent with the lowest immune infiltration in tissue 1, 407 followed by 4, 3, 2, and 5 (Fig. 5B and S25), closely corroborating the order of damage 408 revealed by Signature 1. Trajectory analysis of the cell type compositions with 409 Signatures 1 and 3 using Slingshot [64] defined a trajectory of reduced normal alveoli 410 and increased immune infiltration from the non-COVID-19 tissue to tissue 1, 4, 3, 5, and

411 2 (Fig. 5C), which was in agreement with the order of their increased severity of 412 pathology observed in H&E staining (Fig. S1). Remarkably, Signatures 4 to 7 captured 413 four distinct types of immune microenvironments or niches in these COVID-19 tissues. 414 Signature 4 was characterized by high ACs (64.8%) with MMs (27.3%), likely reflecting 415 the infiltration of alveolar MMs and proliferation of ACs in wound healing, all of which 416 are features of exudative DAD [65]. The relatively higher prevalence of Signature 4 in 417 the less severe tissues 1 and 4 suggested its association with early phases of DAD (Fig. 418 5B and S25). There were also overlaps in regions with higher loadings of Signature 4 419 with the annotated regions of immune infiltration in the H&E image in tissue 4 (Fig. 5B 420 and S1). Signatures 5 and 6 depicted inflammations around VECs, where Signature 5 421 was associated with extensive infiltration of MMs (46.7%) and T cells (8.7%) around 422 VEC (26.3%), whereas Signature 6 was associated with substantial infiltration of NK 423 cells (31.8%) and granulocytes (13.6%) around VECs (27.6%) and ECs (12.2%). These 424 results were consistent with the influx of MMs and NK cells (Fig. 1E and F), which was 425 likely due to the activation of complement and coagulation systems (Fig. 2A and C), 426 resulting in damages and therefore reduced numbers of ACs and VECs (Fig. 1E and F). 427 Signature 5 was more common in the less severe tissues 1, 3 and 4 but Signature 6 428 appeared predominantly in 3 (Fig. 5B and S25), particularly in low infection region (Fig. 429 3A). Indeed, lymphocytic infiltrations were also identified in the regions associated with 430 Signatures 5 and 6 (Fig. S1). Signature 7 denotes extremely high fibroblasts (73.4%) 431 with infiltration of MMs (15.8%). Advanced disease in COVID-19 patients often has an 432 excessive accumulation of fibroblasts and may develop pathological fibrosis due to 433 chronic inflammation from the infiltrated immune cells and dysregulation of the

extracellular matrix triggered (ECM) remodeling [66]. As expected, there was a high
correlation between the COL1A1 expression level (Fig. 4F) with Signature 7. The
loadings of this signature were high in tissues 1 and 2, which were annotated as OP
regions, and in tissue 5, which were annotated as fibrin and hyaline membrane in
addition to OP regions (Fig. 5B, S1 and S25), suggesting a connection with OP, fibrin
and hyaline membrane.

440

441 Unique cell composition signatures define two separate pathological trajectories.

442 We then applied Signatures 4 to 7 to delineate the trajectories of DAD 443 characterized by the immune responses against viral infection. We added Signature 1 444 "normal-like alveoli" so that the non-COVID-19 tissue could be included as a reference. 445 We used these 5 signatures to redefine the landscape of spatially resolved cell type 446 compositions in these tissues. The UMAP visualization (Fig. 6A) recapitulated the tissue 447 severity inferred by Signatures 1 and 3 (Fig. 5C) but presented more complex patterns, 448 with each immune signature defining a largely distinct group of cell populations (Fig. 449 6B). We applied *Slingshot* to infer pseudo-progressions of cells defined by these 450 signatures and identified two trajectories (Fig. 6A). Clustering of cells based on pseudo-451 time values further segmented the trajectories into 6 stages (Fig. 6A). At the onset, the 452 two trajectories shared a common path including stages T1 and most T2, which 453 traversed the cells enriched by Signature 1 "normal-like alveoli" and Signature 4 "ACs 454 with MMs infiltration" in T1 and then those enriched by Signature 4 and Signature 5 455 "VECs with MMs infiltration" in T2 (Fig. 6A). These stages were consistent with the less 456 damaged presentations of tissues 1 and 4 (Fig. 6D and S1) and showed a reduction of

457 ACs due to likely lung injury and an increase of MMs possibly promoted by innate 458 immune responses (Fig. 6C). Inspecting associated tissue regions in the H&E images 459 showed characteristics of early DAD manifested by shedding of ACs, capillary leakage, 460 lymphocytic/immune infiltration, and yet preserved alveoli structure (Fig. 6D and E, T1 461 and T2). After the shared section, the trajectories diverged into two paths. The first path 462 (Trajectory A) included T3a and T4a and progressed through cells mostly from tissues 3 463 and 4 enriched in Signature 5 "VEC with MMs infiltration" ending in Signature 6 "VEC 464 with NK cell infiltration", which was almost exclusively from tissue 3 (Fig. 6A, B and D). 465 We observed a persistent decrease in ACs but an increase in VECs, NK cells and B 466 cells (Fig. 6C). The H&E staining of tissue regions for T3a and T4a showed hyaline 467 membrane, fibrin, lymphocytic infiltration, and collapsed alveoli and capillary structure 468 (Fig. 6E, T3a and T4a, and S1). These features are consistent with a more advanced 469 DAD. The close association of this path with tissues 3 and 4 suggested that they 470 encompassed similar DAD-related tissue patterns and immune niches. Indeed, the 471 postmortem report showed similar findings for these two patients including bilateral 472 pulmonary consolidation [9].

The second path (Trajectory B) included two stages, i.e., T3b and T4b, which are enriched by Signature 6 in T3b and Signature 7 "high fibroblasts with MMs infiltration" in T4b highlighted by increased fibroblasts and immune infiltration of especially MMs (Fig. 6A, B, and C). Their associated tissue regions were mostly in tissues 1, 2, and 5 (Fig. 6D), suggesting potentially similar DAD tissue patterns and underlying immune niches in these tissues. The postmortem findings indeed revealed massive pulmonary emboli that were the main cause of death for cases 1 and 2 [9]. Close examination of these

480 regions in the H&E staining showed edema, increased fibrin, and OP (Fig. 6D, E, T3b 481 and T4b, and S1), which are pathological signatures of DAD. There was a striking 482 association between regions in tissues 1, 2 and 5 in T4b with the identified OP, fibrin 483 and hyaline membrane regions and a significant positive correlation between the 484 progression of Trajectory B and cell density (0.504, Spearman correlation, p-value < 485 0.05) suggesting a more advanced stage of T4b than T3b with tissue 1 manifested in a 486 more localized while tissues 2 and 5 in a more systematic manner. These results 487 demonstrated a high degree of inter and intra-tissue heterogeneity in DAD-associated 488 patterns. While tissue 1 contained regions affiliated with both trajectories, tissues 2 and 489 5 were mostly associated with the trajectory featured by high fibroblasts and their 490 reorganization, and tissues 3 and 4 were with the trajectory featured by increased VEC 491 and immune infiltration.

492 Next, we investigated the genes whose expressions in a cell type were correlated 493 with the trajectories. We found 53 and 67 genes significantly correlated with Trajectory 494 A and B in at least one cell type, respectively (Spearman correlation, *p-value*<0.05, 495 permutation test; Table S6). In both trajectories, we obtained a negative correlation for 496 ACs marker SFTPC in ACs (Fig. S26A, S26B, Table S6, and Table S7), suggesting a 497 decrease in its expression, which echoes the reductions in ACs in both trajectories (Fig. 498 6C). We also found a positive correlation of NCAM1 in NK cells with Trajectory A and 499 positive correlations of COL1A1 in Fibroblasts and C1QB in MMs with Trajectory B (Fig. 500 S26A, S26B, Table S6, and Table S7), all of which were consistent with the observed 501 changes of cell type compositions and DAD pathologies along the trajectories (Fig. 6C).

502 To gain further insight into potential ligand-receptor interactions that underlie the 503 immune patterns associated with the trajectories, we correlated the ligand-receptor co-504 expressions with the trajectories. We found that CD40LG-CD40, CD80-CD28 and 505 CXCL10-CXCR3 had the highest positive correlations with Trajectory A in all key cell 506 types including especially VECs, ACs and Fibroblasts (Fig. S26C) while CD40LG-CD40, 507 CSF3-CSF3R and CXCL10-CXCR3 were the top positive correlated pairs with 508 Trajectory B in ACs, Fibroblasts, VECs and MMs (Fig. S26D). Thus, these ligand-509 receptor pairs might contribute to the chemoattraction of the immune cells as a result of 510 SARS-CoV-2 infection.

511

512 IL6-STAT3 and TGF-β-SMAD2/3 pathways mediate COVID-19 lung fibrosis and 513 organizing pneumonia.

514 Because Trajectory B progressed into tissue regions that manifested extensive 515 OP, we investigated the spatial patterns and molecular signatures associated with OP, 516 which was mostly observed in tissues 1 and 2 and to a less extent in tissue 5, which 517 also contained fibrin and hyaline membrane (Fig. 7A and S1). Analysis of cell 518 compositions in regions with OP revealed an overall increase in cell density, and 519 obvious decreases in cell numbers of ACs and VECs but an increase in cell numbers of 520 fibroblasts compared to other regions in the same tissues and the non-COVID-19 tissue 521 (Fig. 7B, C and D). As in the whole tissues, we observed downregulations of AGER, 522 CAV1, SFTPA1, SFTPC, and A2M, and upregulation of IGKC in OP regions compared 523 to the normal tissue (Fig. 7E). The changes of AGER, SFTPA1, SFTPC, and A2M were 524 primarily observed in fibroblasts, MMs and VECs with downregulation of A2M also being

525 observed in ACs (Fig. 7F, G and H). The most striking observation is the upregulation of 526 genes encoding for collagen type I alpha 1 and 2 chains (COL1A1 and COL1A2) in OP 527 in both tissues compared to the normal tissue or to regions without OP in the same 528 COVID-19 lung tissues (Figure 7E and G). Furthermore, both COL1A1 and COL1A2 529 were upregulated in fibroblasts in OP regions compared to fibroblasts from either 530 normal tissue or non-OP regions from the same tissue (Fig. 7G, H and I). COL1A1 and 531 COL1A2 form the triple helix of a fibril-forming collagen, which is essential for lung 532 homeostasis. Dysregulation of COL1A1 and COL1A2 leads to lung inflammation and 533 fibrosis [67, 68]. Both COL1A1 and COL1A2 were mainly expressed in fibroblasts (Fig. 534 7G and 7H), whose cell numbers were doubled in OP regions in both tissues compared 535 to non-OP regions (Fig. 7D). Interestingly, the expression levels of COL1A1 and 536 COL1A2 were highly heterogeneous in the individual cells in OP regions with extremely 537 higher levels in 10-20% of the fibroblasts, which were absent in fibroblasts in non-OP 538 regions or any other types of cells in the same COVID-19 tissues (Fig. 7J). COL1A1 and 539 COL1A2 were not expressed in high levels in any types of cells in normal lung tissue 540 (Fig. 7J). These results indicated that COVID-19 OP regions had severe dysregulation 541 of fibroblasts with upregulation of COL1A1 and COL1A2, and abnormal ACs and VECs 542 as a result of downregulation of AGER, SFTPA1, and SFTPC. 543 To further confirm that increased expressions of COL1A1 and COL1A2 were

hallmarks of COVID-19 OP, we examined their expressions in different cell types in
single-cell RNA-seq (scRNA-seq) data from COVID-19 lung tissues [4]. Consistent with
our observation, we found that COL1A1 and COL1A2 expressed mainly in fibroblasts
and also showed varying expression levels (Fig. S27A). Specifically, they showed a

548 higher expression level in a subset of fibroblasts enriched with myofibroblasts (p < 549 0.001, Gene Set Enrichment Analysis (GSEA): Fig. S27A and B). Myofibroblasts are 550 differentiated fibroblasts, whose dysregulation may lead to idiopathic pulmonary fibrosis 551 (IPF) including COVID-19 lung fibrosis, a lung disease that exhibits OP [69-71]. To 552 provide a linkage between the OP regions and IPF, we examined the scRNA-seq data 553 from lung tissue patients with IPF and nonfibrotic controls [72]. Like in the COVID-19 554 data, we observed a subpopulation of fibroblasts with high expressions of COL1A1 and 555 COL1A2 (Fig. S27C) and they were also enriched in myofibroblasts (p-values<0.001, 556 GSEA; Fig. S27D). We further examined the differentially expressed genes in IPF 557 fibroblast cells with high COL1A1 and COL1A2 expressions vs. fibroblast cells with low 558 COL1A1 and COL1A2 expressions or nonfibrotic cells, respectively (Fig. S27E and 559 S27F). The two lists of significant differentially expressed genes (DEGs) were similar (p-560 values<0.001, GSEA; Fig. S27G), suggesting that the subpopulation with low COL1A1 561 and COL1A2 expressions could serve as normal control. As a result, we compared the 562 fibroblasts with a high vs. low COL1A1 and COL1A2 expressions in the COVID-19 563 scRNA-seq data and obtained the DEGs (Fig. S27H). These DEGs are enriched by two 564 DEG lists in IPF fibroblasts with high COL1A1 and COL1A2 expressions (p< 0.001, 565 GSEA; Fig. S27I and S27J), suggesting that these cells likely had similar molecular 566 characteristics as those in IPF. Indeed, functional enrichment analysis using the 567 Ingenuity Pathway Analysis reported "Pulmonary Fibrosis Idiopathic Signaling 568 Pathways" as the 2nd top-ranked pathway (Fig. S27K). Several other top enriched 569 pathways related to extracellular matrix remodeling were also identified. Examination of 570 the networks of these pathways identified IL6-STAT3 and TGF-β-SMAD2/3 pathways

571	that could directly regulate the expressions of COL1A1 and COL1A2 (Fig. 7K). Multi-
572	color indirect immunofluorescence antibody assay (IFA) staining indeed revealed that
573	cells with a high COL1A1 expression level also had high levels of IL6 receptor-
574	α (IL6R $\alpha), phospho-STAT3$ (p-STAT3), TGF- β R2 and phospho-SMAD2/3 (p-SMAD2/3),
575	confirming the activation of these pathways and their potential roles in the upregulation
576	of COL1A1 (Fig. 7L). Both IL6 and TGF- β are highly induced, and implicated in fibrosis
577	and lung injury [73, 74] as well as upregulation of COL1A1 and other extracellular matrix
578	proteins in COVID-19 lung tissues [75, 76]. These results demonstrated the important
579	roles of IL6 and TGF- β in the induction of severe COVID-19 lung OP and fibrosis.
580	
581	Discussion
500	Listen in either environment and ever excitic leights call excitic minaling was have

582 Using *in-situ* sequencing and our spatial single-cell analysis pipeline, we have 583 painted an atlas of cellular and molecular signatures of lung tissues from severe 584 COVID-19 cases. The atlas describes the cellular heterogeneity, organization, and 585 interactions associated with inflammation, damage, and immune responses in COVID-586 19 tissues. It provides molecular and cellular insights into the mechanisms underlying 587 SARS-CoV-2 infection and the pathological manifestations in COVID-19 lungs. 588 We detected a total of 10,414,863 transcripts in five COVID-19 and one non-589 COVID-19 lung tissues. Spatial single-cell transcriptomics analysis at this scale for 590 COVID-19 and other pathological conditions is still very limited. We have overcome 591 considerable challenges and developed a pipeline of robust, scalable, interpretable 592 computational tools and visualization methods for targeted and exploratory analyses 593 emphasizing on spatial discovery. The first critical component of this pipeline is a

transcript-based cell segmentation strategy that integrates cell nuclei in the matching
DAPI staining identified by *CellPose* with spatially localized reads using *Baysor* and
iteratively segments reads into cells of potentially different sizes [10, 77]. Using this
strategy, we segmented 93% of total transcripts into 1,719,459 cells including 186,659
to 470,294 cells for different tissues. A customized filter was further applied to retain
only a subset of high-quality cells.

600 Cell typing of these filtered cells based on marker genes showed that SARS-601 CoV-2 infected all the 18 identified cell types, a result consistent with those of our 602 previous study [9] and others [4]. However, only a small fraction of these cells (<5%) are 603 infected. These results agree with those of genome-wide studies that detected small 604 numbers of viral reads in blood, lung, and nasopharyngeal samples from severe 605 COVID-19 patients [4, 78-81]. Despite the detected low infection rates, SARS-CoV-2 606 inflicts similar effects on the infected and uninfected cells across the tissues as shown 607 by differential expression analysis of genes in infected or uninfected cells in COVID-19 608 tissues against cells in the non-COVID-19 lung tissue (Fig. 2A). Thus, indirect effects 609 such as those induced by the immune response, inflammation, cytokines, and 610 complement activation might play a significant role on lung pathology in COVID-19 611 patients. In fact, we have observed vast pulmonary microthrombi, thrombosis, and 612 immune infiltrations in these COVID-19 lung tissues (Fig. S1). The major parenchymal 613 cells including ACs, fibroblasts, and VECs have the highest numbers of infected cells. 614 The COVID-19 lung tissues have reduced numbers of ACs and SMCs, but an increased 615 number of ECs accompanied by vast immune infiltrations of innate immune cells

616 including MMs, granulocytes, and NK cells, and adaptive immune cells including T and617 B cells.

618 Despite these global and consistent impacts of SARS-CoV-2 infection on the 619 lungs, there are extensive spatial heterogeneities in addition to varying cell type 620 percentages across the tissues. To reveal spatial dynamics of cellular features 621 presented in considerable spatial discontinuity due to sparse measurements, we 622 adopted a strategy to compute local feature distributions in the neighboring region of the 623 cell with a fixed radius or cell number. This approach assesses the spatial gene 624 expression maps, local infection rates, cell densities, and co-expression maps of ligand-625 receptor pairs. To further characterize spatial patterns of an individual feature or joint 626 pattern relationship between two features, we extensively applied the Moran's I 627 statistics, a method widely adopted in geoscience but scarcely in spatial transcriptomics 628 analysis. Using these novel strategies, we identified regions with high infection rates, 629 which are found in regions with high cell densities expressing higher levels of SARS-630 CoV-2 entry-related factors including ACE2, FURIN, TMPRSS2, and NRP1. Thus, 631 SARS-CoV-2 may preferentially infect cells expressing these factors and the infected 632 cells could also aggregate to these high-density regions following infection. Importantly, 633 these regions are mapped to OP (tissues 1 and 2) or regions with fibrin, hyaline 634 membrane, and edema (tissues 3, 4, and 5), and manifest cellular and molecular 635 patterns resembling tissue damage and wound healing including infiltration of immune 636 cells and pattern of fibrosis. We have found that OP harbors high densities of fibroblasts 637 expressing high levels of COL1A1 and COL1A2, a phenomenon common in fibrosis and 638 wound healing, which are unique to OP regions unseen in other regions of COVID-19

639 lung tissues or in the non-COVID-19 tissue. We have identified similar cell populations 640 enriched by myofibroblasts in 10X scRNA-seq data from COVID-19 lung samples and 641 IPF samples, suggesting that SARS-CoV-2 might preferentially infect myofibroblasts or 642 reprogram other cell type(s) into myofibroblasts. Pathway enrichment analysis revealed 643 the enrichment of multiple pathways related to IPF signaling and extracellular matrix 644 remodeling including IL6-STAT3 and TGF-b-SMAD2/3 pathways. Indeed, we have 645 detected high levels of IL6Ra, p-STAT3, TGF-bRII, and p-SMAD2/3 in cells expressing 646 myofibroblast markers in OP regions. These results suggest that SARS-CoV-2 infection 647 might induce aggregation of fibroblasts, and IL6 and TGF-b to promote wound healing 648 in OP regions.

649 To define spatial patterns associated with COVID-19 lung pathology, we 650 performed the NCTC analysis, or the niche analysis, commonly used for probing 651 interactions of cells such as in immune microenvironments. However, the COVID-19 652 tissues contain complex pathology manifestations resulting in highly heterogenous 653 cellular organizations and thus disparate NCTC patterns. To tackle this challenge, we 654 applied SNMF, owing to its scalability and interpretability, to NCTCs of all cells in six 655 tissues to reveal potentially latent features underlying these seemingly less organized 656 NCTCs. We indeed identified 7 latent signatures of spatial cell type compositions that 657 define normal lung structures and SARS-CoV-2 infection-induced immune niches. While 658 many existing studies have revealed the global immune landscape of SARS-CoV-2 659 infection [1, 2, 5], few report spatial signatures of immune niches. We showed that these 660 niches are mostly tissue-independent, but COVID-19 tissues presented heterogeneous 661 distributions of these niches: while tissues 1, 2, 4, and 5 contain multiple types of

662 niches, tissue 3 has predominately a single type. We further drew the connections 663 between these niches and different stages of DAD. Such a linkage prompted us to apply 664 the trajectory analysis to NCTCs of these signatures. While the trajectory analysis is 665 most commonly applied to gene expressions to predict a pseudo-progression of the 666 cells, here, this innovative use of trajectory analysis defined the relative severities of 667 damages among COVID-19 tissues and constructed two different pathological routes of 668 progression in COVID-19 patients. Both routes start with enriched "ACs with MM 669 infiltration" and "VECs with MMs infiltration" niches but Route A is marked by increased 670 numbers of NK cells and granulocytes, likely reflecting complications of microbial 671 infections, while Route B is characterized by increased HIHD and OP, marked by 672 increased fibrosis. Both routes are also correlated with multiple cytokine-cytokine 673 receptor pairs such as CD40LG-CD40 and CXCL10-CXCR3 that are likely to mediate 674 the chemoattraction of the immune cells (Fig. S26C and S26D). By mapping these 675 routes to individual cells, we further revealed considerable inter and intra-tissue 676 heterogeneity in the inferred progression of COVID-19 pathology with tissue 3 and 4 677 associated with Route A, tissue 2 and 5 with Route B, and tissue 1 with both routes. 678 In summary, we have presented an atlas of spatial patterns of different cellular 679 features that characterize SARS-CoV-2 infection, its induced immune infiltrations, 680 inflammation, and damages in severe COVID-19 lungs, in addition to changes in gene 681 expression in multiple cell types, including immune cells and lung parenchymal cells. 682 These results provide insights into the spatial mechanisms at both molecular and 683 cellular levels, which characterize the development of ARDS in COVID-19 patients. 684 Overall, this study demonstrates the power of spatial single-cell transcriptomics and

enables spatial computational analyses in the study of COVID-19 lung pathology. The
developed innovative methods can benefit spatial single-cell analyses for other healthy
and diseased conditions.

688

689 Methods

690 Lung tissue samples

691 COVID-19 lung tissues were collected from 5 adults with fatal SARS-CoV-2
692 infection by the Autopsy Service of the Department of Pathology, Molecular and Cell693 Based Medicine at the Icahn School of Medicine at Mount Sinai, and non-COVID-19
694 lung tissue was obtained from Pitt Biospecimen Core [9].

695

696 Study approval

697 Specimens obtained at autopsy do not meet the definition of a living individual 698 per Federal Regulations 45 CFR 46.102, and as such, research using specimens 699 obtained at autopsy does not meet the requirements for Institutional Review Board 700 (IRB) review or oversight under the Icahn School of Medicine Program for the Protection 701 of Human Subjects. The University of Pittsburgh IRB determined that the study is not 702 research involving human subjects as defined by DHHS and FDA regulations and 703 waived of ethical oversight (STUDY20050085). 704 705 In-situ sequencing (ISS) 706 HS Library Preparation kit (P/N 1110-02, CARTANA AB, part of 10x Genomics)

707 was used to prepare the library according to the manufacturer's instruction with minor

708 modification [82]. Four µm FFPE tissue sections were baked for 1 hour at 60°C and 709 deparaffinized by incubating in xylene twice for 7 minutes (min) each. The sections were 710 then rehydrated by incubating in 100% ethanol (EtOH) for 5 min, followed by 70% EtOH 711 for 5 min, and nuclease-free deionized distilled water (SH30538.02, HyClone) for 2 min. 712 Sections were then permeabilized by incubating in citrate buffer pH 6.0 (C9999, Sigma 713 Aldrich) for 3 hours at 95°C. Chimeric padlock probes (from 1 custom panel (Table S1) 714 and 4 predesigned panels: hImmune I1A, hImmune I3D, hLung L1C, hLung L2E, 715 CARTANA AB) directly targeting RNA and containing an anchor sequence as well as a 716 gene-specific barcode were hybridized overnight at 37°C, then ligated overnight at 717 30°C. Quality control of the library preparation was performed by applying anchor 718 probes which labeled by Cy5 to simultaneously detect all rolling circle amplification 719 products from all genes in the panel. All incubations were performed in SecureSeal[™] 720 hybridization chambers (621502, Grace Biolabs). Slow Fade Antifade Mountant 721 (S36936, ThermoFisher) was used for mounting. All samples passed the quality control 722 and were sent to CARTANA AB (part of 10x Genomics) for *in-situ* barcode sequencing, 723 imaging, and data processing. Briefly, the fluorescent signals for quality control were 724 stripped. Adapter probe pool 1 and a sequencing pool containing 4 different fluorescent 725 labels were hybridized to the *in-situ* libraries to detect gene-specific barcodes. The 726 scanning was fulfilled by using epifluorescence microscopy, and raw data consisting of 727 20x magnification images from 5 fluorescent channels (DAPI, Alexa Fluor® 488, Cy3, 728 Cy5 and Alexa Fluor® 750) and individual z-stacks, were flattened to 2D using 729 maximum intensity projection with a Nikon Ti2 Microscope (software NIS elements) 730 utilizing a Zyla 4.2 camera. In total, 6 sequencing cycles were achieved for full decoding

731 of all designed genes. After image processing, which includes image stitching, 732 background filtering, and a sub-pixel object registration algorithm, true signals were 733 scored based on signal intensities from individual multicolor images. The results were 734 summarized in a CSV file and gene plots were generated using MATLAB. Each ISS 735 spot provided a unique fluorescent barcode identifying the targeted RNA of a gene 736 marker. The experiment generated a map of gene expressions of selected genes 737 recorded on the natural morphology of the tissue at a single-cell level. The metadata 738 generated from the images were further analyzed to obtain data containing the reads 739 and their 2D (X, Y) positions of each gene, and the DAPI images. TissuuMaps [83, 84] 740 was used to visualize spatial read locations of multiple genes against DAPI or histology 741 images.

742

743 Hematoxylin-eosin staining (H&E) and whole slide scanning

H&E was carried out with the same slides subjected to *in-situ* sequencing using
Hematoxylin & Eosin Stain Kit (H-3502, Vector Laboratories) according to the
manufacturer's instructions. The slides were then scanned with VS200 Slide Scanner
(Olympus).

748

749 Indirect immunofluorescence antibody assay (IFA)

750 IFA was carried out as previously described [9]. Primary antibodies included

751 CoraLite® Plus 647-conjugated smooth muscle actin (1:200, Proteintech, CL647-

752 67735), CoraLite® Plus 488-conjugated Collagen Type I (1:100, Proteintech, CL488-

753 67288), IL6Rα (1:500, Proteintech, 23457-1-AP), p-STAT3 (Tyr705) (1 to 20, Invitrogen,

754 710093), p-SMAD2/3 (p-SMAD2-S465/467 and p-SMAD3-S423/425, 1:500, ABclonal,

755 AP0548), and TGF-βRII (1:10, R&D Systems, AF-241-NA). Secondary antibodies

756 included Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa

757 Fluor[™] Plus 555 (1:400, Invitrogen, A32732), Donkey anti-Mouse IgG (H+L) Highly

758 Cross-Adsorbed Secondary Antibody, Alexa Fluor[™] 568 (1:400, Invitrogen, A10037).

759

760 Cell segmentation

761 Reads in a tissue sample were segmented into corresponding cells using the 762 Baysor cell segmentation algorithm [10]. Baysor applies a Markov Random Field model 763 to identify spatial clustering of reads from the same cell. It can perform cell 764 segmentation based on read coordinates alone but can also incorporate nuclear 765 information from DAPI staining. We first utilized the DAPI-stained images of the tissues 766 and performed the nuclei segmentation using the CellPose anatomical segmentation 767 algorithm with the default setting of parameters [77]. Segmented nuclei masks with 768 locations were provided to Baysor to define its scale and standard deviation 769 parameters. Baysor was able to segment 71%- 91% of reads after the first run for all 770 samples/tissues. However, we found that among the unsegmented, the so-called noisy 771 background reads determined by Baysor, there is a considerable portion that could still 772 be assigned to cells visually. To address this issue, we applied Baysor again to these 773 noisy reads from the first Baysor run. We optimized the scale and standard deviation 774 parameter for the second Baysor run to maximize reads assignment to cells. Including 775 the second run significantly improved the percentages of the segmented reads to 88%-

777	because the remaining unsegmented reads were mostly noisy background reads.
776	95% for all samples/tissues (Fig. S3, S4 and Table S2). We implemented only two runs

778

779 Normalization and filtering

Segmented gene reads assigned to cells were then filtered using multiple criteria. First, we removed cells that did not contain reads from any marker genes. Second, we removed cells with total read counts <5 or less than 4 genes with reads. Of the remaining cells, read counts for each gene within a cell were tallied and gene expressions were normalized using the *scTransform* algorithm [11] to further remove biases due to technical variability. The normalized expressions of 220 genes were used for subsequent analysis.

787

788 Cell typing

We determined the cell type of each cell using an in-house curated list of marker genes for 18 cell types (Table S1). For each cell, we calculated the average expression of marker genes for each of the 18 cell types and then assigned the cell type with the highest average expression to this cell. We further annotated infected cells as those with at least one SARS-CoV-2 read. We used UMAP to visualize the expression pattern of cells associated with the identified cell types in a lower dimension by using the visualization pipeline in the Seurat package [85].

796

797 Image registration

798 The DAPI images of tissues that were used as a prior for cell segmentation had 799 translational and rotational differences with their corresponding H&E stained images. 800 For single-cell resolution datasets, small spatial geometric changes in the available raw 801 morphology images could have dramatic differences in downstream analysis for 802 studying the pathology signatures using annotated regions in the H&E image. To 803 mitigate these spatial geometric differences, we registered the DAPI and H&E images 804 by maximizing the phase correlation between both images. Here, we selected the DAPI 805 image as a fixed reference because we used DAPI images as references for reads 806 mapping and cell segmentation. To register both images, the H&E stained image is 807 transformed by changing the scale, rotation, and translation parameters and moved 808 across the DAPI image to improve the phase correlation of both 2D images. Once a 809 peak correlation value was found, the optimization algorithm returned the 2D geometric 810 transformations required to warp the H&E-stained image and registered it to the 811 corresponding DAPI image. We applied the same image registration algorithm to all six 812 samples used in this study. Pathology annotations were carried out on the registered 813 H&E images.

814

815 Cell density analysis

The abundance of cells relative to the tissue context could reveal biology related to cell proliferation, cell damage, as well as other pathologies related to infection. In our spatial analysis pipeline (Fig. 1B), we defined cell density based on the number of cells within a neighborhood of a fixed radius of 200 units ($200 \times 0.32 \mu$ m/unit = 64 um) centering a cell, covering an area of 0.013 mm². By calculating the number of cells

within the fixed neighborhoods of each cell, we summarized the global cell densitypatterns across the tissue. We further presented the cell density as a contour plot by

fitting a 2D kernel density estimator (KDE) on the cell density feature (Fig. 3).

824

825 Neighboring cell type composition analysis

826 Local cell type distributions can reveal tissue structures and different COVID-19 827 pathology. We assessed the local cell type distribution by computing the neighboring 828 cell type composition (NCTC) of each cell. NCTC defined a cellular neighborhood of 200 829 cells and counts the number of different cell types in the neighborhood to create a 830 neighborhood count vector for each cell. This neighborhood count vector was 831 normalized to obtain the percentages of cell types. NCTC summarized the distributions 832 of each cell type in the vicinity of a cell and was further used to analyze the spatial 833 correlation of different cell types in a region-of-interest (ROI), study spatial gene 834 expression patterns of local neighborhoods, identify local hotspots of individual cell 835 types, and more. Furthermore, the neighborhood composition of individual cell types is 836 spatially mapped by painting the neighborhood count/percentage of the selected cell 837 type with a continuous "rainbow" color scheme where deeper violet to deeper reds 838 indicates a range of low-to-high neighborhood cell composition (Fig. S10-S15).

839

840 Spatial gene expression map

SSCT captures gene expression of single cells in the context of intact tissue
structures. In our study, we investigated the spatial organization of cells in tissue and
their gene expression by studying their spatial gene expression maps (SGM). For each

844 gene, its SGM is defined as the sum of the expression of that gene in its 200 nearest 845 neighboring cells. Thus, SGM represents a spatial gradient by summarizing the regions 846 with high or low gene expression patterns. We then painted the SGM using the 847 continuous rainbow colormap similar to the NCTC analysis, generating the spatial gene 848 expression maps illustrated in Fig. 2B, 2C, and 4F. By comparing the SGM with 849 available pathology annotations, pathology signatures with relevant expression patterns 850 can be localized to specific spatial regions in the tissue. Additionally, novel pathology 851 signatures or ROIs can be discovered using the proposed SGM analysis. 852

853 Local infection rate analysis

We used the local infection rate analysis to study the spatial distribution of
SARS-Cov-2 infection. It was similar to the NCTC analysis and computed the
percentage of infected cells in a fixed physical area of 1.286 mm² or a radius of 2,000
units (640 µm) around each cell across the tissue. These spatial rates can be further
visualized using the same rainbow color scheme as NCTC (Fig. 3A).

859

860 Ligand-receptor coexpression map

Ligand-receptor interactions among cells in a defined location can define spatial patterns of immune microenvironments due to SARS-CoV-2 infection. To infer the interactions, we examine the spatial co-expression between a ligand-receptor pair. Inspired by Moran's I spatial cross-correlation, we computed the spatial coexpression between ligand x and receptor y for cell i as

$$E_i = x_i \sum_{j \in \mathcal{N}_i} y_j$$

867 where $x_i = 1$ ($y_j = 1$) if ligand x (receptor y) expressed in cell i (j) and 0, otherwise and 868 \mathcal{N}_i defines a set of neighboring cells of cell i, which are cells within a radius of 1,000 869 units (320 µm) or a fixed physical area of 0.322 mm² around cell i. Then, we visualized 870 the coexpression in a tissue using a fixed monochrome color scheme (Fig 3F).

871

872 Moran's I analysis of spatial patterns

873 Spatial global autocorrelation of one variable or more variables can be 874 summarized using Moran's I score. However, calculating the global spatial 875 autocorrelation using Moran's I across the whole tissue assumes homogeneity of the 876 studied variable and yields only one statistic that summarizes the complete spatial 877 pattern across the tissue disregarding their difference over space. Since our SARS-878 CoV-2 infected tissue samples show spatial heterogeneity, in this study, we used Local 879 Indicators of Spatial Association (LISA) [86] to evaluate the spatial autocorrelation and 880 the statistical significance of a study variable in each location using Local Moran's I. 881 Consider x_i as, e.g., the neighboring infection rate of a cell at location *i*, the 882 univariate spatial autocorrelation can be found as the degree of linear association 883 between x_i and a weighted average of the neighboring cells x_i , based on a spatial weight w_{ij} between cells at location *i* and *j*. Thus, formally, Moran's I for each location *i* 884 885 is given by

886
$$I_i = \frac{x_i - \bar{x}}{m_2} \sum_{j=1}^N w_{ij} (x_j - \bar{x})$$

887 where *N* defines the number of cells, \bar{x} defines the mean of all the cells, and m_2 is given 888 by

889
$$m_2 = \frac{\sum_{i=1}^{N} (x_i - \bar{x})^2}{N}$$

890 I_i ranges from -1 to 1 with -1 indicating highly negative and +1 indicating highly positive 891 spatial autocorrelation. Such formulation can be used to identify spatial regions with 892 high or low autocorrelation. For example, in Fig. 3B, we identified regions with high and 893 low infection rates in each tissue.

Under the same formulation, bivariate spatial autocorrelation can be used to assess spatial cross-correlation of a feature x_i , e.g., the neighboring infection rate of a cell at location *i* and another feature y_j , e.g., the cell density of a neighboring cell *j* as

897
$$I_i = \frac{x_i - \bar{x}}{m_2} \sum_{j=1}^N w_{ij} (y_j - \bar{y})$$

where I_i defines the degree of linear association between the neighboring infection rate of a cell at location *i* and a weighted average of the cell density of the neighboring cells. Bivariate spatial associations can uncover cross-correlations between any such variable x at location *i* and another variable *y* at neighboring locations by ignoring correlations between *x* and *y* for cases where i = j. In our study, the bivariate LISA method is used to calculate the Local Moran's I to identify HIHD regions described in Fig. 3E.

905 Sparse Non-negative matrix factorization (SNMF) of neighboring cell type

906 compositions

907 SNMF was applied to extract interpretable, tissue-specific, and tissue-908 independent signatures from NCTC vectors from all tissue samples [63]. Let $A \in$ 909 $(0, 1)^{N \times M}$ represent the NCTC matrix of *N* cell types and *M* cells and it is factored as 910

913 where $S \in (0, 1)^{N \times K}$ is the matrix of *K* NCTC signatures with each column denoting a 914 signature, $H \in (0, 1)^{K \times M}$ is the signature loading matrix with *m*th column denoting the 915 contributions of each signature to the NCTC vector of cell *m*, and $D \in \mathbb{R}^{K \times K}$ is a scaling 916 matrix.

917 R package *RcppML* was used for the SNMF analysis [63], which implemented 918 an alternating least squares (ALS) algorithm to minimize the mean squared error (MSE) 919 between *A* and *SDH*. L_1 regularization was introduced to promote a compact, sparse 920 signature loading.

Determining the best number of signatures *K* is important for uncovering meaningful signatures. While an underestimated number could miss critical signatures, an overestimated number would include many noisy signatures. To this end, we evaluated different maximum numbers of factors from 4 to 12 and examined the meaning regarding its cell type composition and spatial distributions of loadings of each signature and chose K = 7 for the SNMF analysis.

927

928 Trajectory analysis

929 The goal of trajectory analysis is to infer a progression or 'pseudotime' of 930 infection severity and associated tissue damages based on NCTC patterns in all 931 tissues. We applied the trajectory analysis to uncover the pseudotime of 1) infection 932 severity among tissues and 2) tissue damage defined by immune microenvironments. 933 For 1), we used loadings of Signature 1 "Normal-like Alveoli" and Signature 3 "Broad

Immune Infiltration" obtained from SNMF and defined tissue samples as clusters. For
2), we used the loadings of Signature 1 and four immune microenvironment-related
signatures, *i.e.*, Signature 4-7, and performed Louvain clustering to define the clusters.
The R package *Slingshot* was used to infer the trajectory [64]. The loadings, clusters,
and the signatures or the 2-D UMAP matrix were fed into *Slingshot* to obtain so-called
'pseudotime' scores for each cell. For both cases, the cluster enriched by cells from the
non-infected tissue (PBC-PR) cells was set as the origin.

941 The pseudotime scores of the cells in each trajectory can correlate with gene 942 expression to uncover genes that correlate with tissue damage. Additionally, ligand-943 receptor coexpressions that correlate with each trajectory could inform potential ligand-944 receptor interactions that govern immune responses. To this end, we computed the 945 Spearman correlation of the pseudotime score with the expression of each gene per cell 946 type in each trajectory. We also computed the correlation of ligand-receptor 947 coexpressions with the pseudotime score of each trajectory. In both cases, to properly 948 assess *p-values*, we performed a permutation test to obtain the empirical null 949 distribution of the correlation coefficients and chose *p-value*<0.5 as the significant level. 950 We then plotted heatmaps to illustrate the cell-type-wise correlations of the genes in 951 each trajectory (Fig. S26A-D). 952

953 Publicly available scRNA-seq datasets

- 954 Two scRNA-seq datasets were obtained and processed as follows.
- 955
 COVID-19 scRNA-seq dataset [4]. The dataset (SCP1052, lung.h5ad.gz) was
 956
 downloaded from the Single Cell Portal

957	(https://singlecell.broadinstitute.org/single_cell). The processed data file
958	lung.h5ad was accessed using the Python package Scanpy (Scanpy 1.9.1).
959	UMAP coordinates for the processed data were accessed from the file
960	upload.scp.X_umap.coords.txt. No follow-up processing was performed on the
961	processed anndata object after it was loaded into Scanpy.
962	2. IPF scRNA-seq dataset [72]. The dataset (GSE135893,
963	GSE135893_ILD_annotated_fullsize.rds.gz) was downloaded from Gene
964	Expression Omnibus (GEO). The Seurat object file was converted into the h5ad
965	file format using the SeuratData package (Seurat 4.3.0, SeuratData 0.2.2). After
966	conversion, the data was loaded in Scanpy (Scanpy 1.9.1) and all cells not
967	originating from an IPF sample or control sample were removed.
060	

969 Statistics and reproducibility

970 Reads-based cell segmentation was performed using *Baysor* (version 0.5.2). 971 Nuclei segmentation from DAPI images was performed using CellPose (version 2.1.1). 972 All other image analyses including imaging registration were performed using MATLAB 973 (version 2022a). Unless otherwise specified, *p*-value < 0.05 was considered significant. 974 The differential expression analysis was performed in R (version 3.6.3) using the 975 Wilcoxon rank-sum test with Bonferroni's correction of multiple testing as necessary. 976 The Moran's I analyses for spatial patterns were performed using GeoDa (version 1.20). 977 Pearson correlation coefficients were calculated using function *pearsonr* in Python 978 Scipy (version 1.9.3). UMAP dimension reduction and visualization were performed

- 979 using function *DimPlot* in Seurat (version 4.2.0). Trajectory analyses were performed
- 980 using R package *Slingshot* (version 2.6.0).

982 Reference

- Ren, X., et al., COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell, 2021. 184(23): p. 5838.
- 985 2. Melms, J.C., et al., *A molecular single-cell lung atlas of lethal COVID-19.* Nature, 2021. 595(7865): p. 114-119.
- 987 3. Wilk, A.J., et al., A single-cell atlas of the peripheral immune response in patients
 988 with severe COVID-19. Nat Med, 2020. 26(7): p. 1070-1076.
- 989 4. Delorey, T.M., et al., COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature, 2021. 595(7865): p. 107-113.
- 5. Stephenson, E., et al., Single-cell multi-omics analysis of the immune response
 in COVID-19. Nat Med, 2021. 27(5): p. 904-916.
- 6. Erjefalt, J.S., et al., *Diffuse alveolar damage patterns reflect the immunological and molecular heterogeneity in fatal COVID-19.* EBioMedicine, 2022. 83: p.
 104229.
- Asp, M., J. Bergenstrahle, and J. Lundeberg, *Spatially Resolved Transcriptomes- Next Generation Tools for Tissue Exploration.* Bioessays, 2020. 42(10): p.
 e1900221.
- 9998.Larsson, L., J. Frisen, and J. Lundeberg, Spatially resolved transcriptomics adds1000a new dimension to genomics. Nat Methods, 2021. **18**(1): p. 15-18.
- Ramos da Silva, S., et al., Broad Severe Acute Respiratory Syndrome
 Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal
 Coronavirus Disease 2019. J Infect Dis, 2021. 223(11): p. 1842-1854.
- 1004 10. Petukhov, V., et al., *Cell segmentation in imaging-based spatial transcriptomics.*1005 Nat Biotechnol, 2022. **40**(3): p. 345-354.
- 100611.Hafemeister, C. and R. Satija, Normalization and variance stabilization of single-
cell RNA-seq data using regularized negative binomial regression. Genome Biol,
2019. 20(1): p. 296.
- 1009 12. Arish, M., et al., COVID-19 immunopathology: From acute diseases to chronic sequelae. J Med Virol, 2022. 95(1): p. e28122.
- 1011 13. Whitsett, J.A., S.E. Wert, and T.E. Weaver, *Alveolar surfactant homeostasis and* 1012 *the pathogenesis of pulmonary disease.* Annu Rev Med, 2010. **61**: p. 105-19.
- 1013 14. Lin, Z., et al., *Genetic Association of Pulmonary Surfactant Protein Genes,*1014 SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD With Cystic Fibrosis. Front
 1015 Immunol, 2018. 9: p. 2256.
- 1016
 15. Floros, J., et al., Human Surfactant Protein SP-A1 and SP-A2 Variants
 1017
 1018
 1018
 1019
 Floros, J., et al., Human Surfactant Protein SP-A1 and SP-A2 Variants
 Differentially Affect the Alveolar Microenvironment, Surfactant Structure,
 Regulation and Function of the Alveolar Macrophage, and Animal and Human
 Survival Under Various Conditions. Front Immunol, 2021. 12: p. 681639.
- 1020
 16. Mikerov, A.N., et al., *Inhibition of hemagglutination activity of influenza A viruses*1021
 1022
 1023
 1024
 1024
 1025
 1025
 1026
 1027
 1027
 1027
 1028
 1029
 1029
 1029
 1020
 1020
 1020
 1020
 1020
 1020
 1020
 1021
 1020
 1021
 1021
 1021
 1021
 1021
 1021
 1022
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
 1021
- 1023 17. Garcia-Laorden, M.I., et al., *The role of mannose-binding lectin in pneumococcal* 1024 *infection.* Eur Respir J, 2013. **41**(1): p. 131-9.

- 1025 18. Sawada, K., et al., *Pulmonary collectins protect macrophages against pore-*1026 *forming activity of Legionella pneumophila and suppress its intracellular growth.* J
 1027 Biol Chem, 2010. **285**(11): p. 8434-43.
- 1028 19. Fassan, M., et al., *Multi-Design Differential Expression Profiling of COVID-19*1029 Lung Autopsy Specimens Reveals Significantly Deregulated Inflammatory
 1030 Pathways and SFTPC Impaired Transcription. Cells, 2022. **11**(6): p. 1011.
- Perkins, T.N., M.L. Donnell, and T.D. Oury, *The axis of the receptor for advanced glycation endproducts in asthma and allergic airway disease.* Allergy, 2021. **76**(5): p. 1350-1366.
- 1034 21. Yue, Q., et al., Receptor for Advanced Glycation End Products (RAGE): A Pivotal
 1035 Hub in Immune Diseases. Molecules, 2022. 27(15): p. 4922.
- 1036 22. Koerich, S., et al., *Receptors for Advanced Glycation End Products (RAGE):*1037 *Promising Targets Aiming at the Treatment of Neurodegenerative Conditions.*1038 Curr Neuropharmacol, 2022. Sep 22. doi:
- 1039 10.2174/1570159X20666220922153903.Online ahead of print
- Yamaguchi, K., et al., Association of the RAGE/RAGE-ligand axis with interstitial *lung disease and its acute exacerbation.* Respir Investig, 2022. **60**(4): p. 531542.
- 104324.Hofmann, M.A., et al., RAGE mediates a novel proinflammatory axis: a central1044cell surface receptor for S100/calgranulin polypeptides. Cell, 1999. 97(7): p. 889-1045901.
- 1046 25. Kapandji, N., et al., *Importance of Lung Epithelial Injury in COVID-19-associated*1047 *Acute Respiratory Distress Syndrome: Value of Plasma Soluble Receptor for*1048 *Advanced Glycation End-Products.* Am J Respir Crit Care Med, 2021. 204(3): p.
 1049 359-362.
- 1050 26. Chiappalupi, S., et al., *Hyperactivated RAGE in Comorbidities as a Risk Factor*1051 *for Severe COVID-19-The Role of RAGE-RAS Crosstalk.* Biomolecules, 2021.
 1052 **11**(6): p. 876.
- 1053 27. Zhang, K. and S.H. Phan, *Cytokines and pulmonary fibrosis.* Biol Signals, 1996.
 5(4): p. 232-9.
- 1055 28. Zhu, Y., et al., Calcium in Vascular Smooth Muscle Cell Elasticity and Adhesion:
 1056 Novel Insights Into the Mechanism of Action. Front Physiol, 2019. 10: p. 852.
- 1057 29. Ringvold, H.C. and R.A. Khalil, *Protein Kinase C as Regulator of Vascular*1058 *Smooth Muscle Function and Potential Target in Vascular Disorders*. Adv
 1059 Pharmacol, 2017. **78**: p. 203-301.
- 106030.Morita, K., et al., Endothelial claudin: claudin-5/TMVCF constitutes tight junction1061strands in endothelial cells. J Cell Biol, 1999. 147(1): p. 185-94.
- 1062 31. Schlingmann, B., S.A. Molina, and M. Koval, *Claudins: Gatekeepers of lung* 1063 *epithelial function.* Semin Cell Dev Biol, 2015. **42**: p. 47-57.
- 106432.Williams, M.R., et al., Gene expression of endothelial cells due to interleukin-11065beta stimulation and neutrophil transmigration. Endothelium, 2008. **15**(1): p. 73-106684.
- 106733.Hashimoto, R., et al., SARS-CoV-2 disrupts respiratory vascular barriers by
suppressing Claudin-5 expression. Sci Adv, 2022. 8(38): p. eabo6783.
- 106934.Pang, L., et al., Role of caveolin-1 in human organ function and disease: friend or1070foe? Carcinogenesis, 2022. 43(1): p. 2-11.

- 1071 35. Gokani, S. and L.K. Bhatt, *Caveolin-1: A Promising Therapeutic Target for Diverse Diseases.* Curr Mol Pharmacol, 2022. **15**(5): p. 701-715.
- 1073 36. Lagrange, J., et al., *Alpha-2-macroglobulin in hemostasis and thrombosis: An underestimated old double-edged sword.* J Thromb Haemost, 2022. 20(4): p.
 1075 806-815.
- 107637.Vandooren, J. and Y. Itoh, Alpha-2-Macroglobulin in Inflammation, Immunity and1077Infections. Front Immunol, 2021. 12: p. 803244.
- 1078 38. Mathison, R., J.S. Davison, and A.D. Befus, *Neural regulation of neutrophil involvement in pulmonary inflammation.* Comp Biochem Physiol C Comp Pharmacol Toxicol, 1993. **106**(1): p. 39-48.
- 1081 39. Sahu, S.K., et al., *Emerging roles of the complement system in host-pathogen interactions.* Trends Microbiol, 2022. **30**(4): p. 390-402.
- Magro, C., et al., Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl
 Res, 2020. 220: p. 1-13.
- 108641.Mastaglio, S., et al., The first case of COVID-19 treated with the complement C31087inhibitor AMY-101. Clin Immunol, 2020. 215: p. 108450.
- 1088
 42.
 Afzali, B., et al., *The state of complement in COVID-19.* Nat Rev Immunol, 2022.

 1089
 22(2): p. 77-84.
- 1090 43. Freeley, S., et al., Asparaginyl Endopeptidase (Legumain) Supports Human Th1
 1091 Induction via Cathepsin L-Mediated Intracellular C3 Activation. Front Immunol,
 1092 2018. 9: p. 2449.
- 1093 44. Zizzo, G., et al., *Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.*1094 Front Immunol, 2022. 13: p. 795315.
- 1095 45. Zhao, M.M., et al., *Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development.* Signal Transduct Target Ther, 2021. 6(1): p. 134.
- 1098 46. Trapani, J.A. and M.J. Smyth, *Killing by cytotoxic T cells and natural killer cells:*1099 *multiple granule serine proteases as initiators of DNA fragmentation.* Immunol
 1100 Cell Biol, 1993. **71 (Pt 3)**: p. 201-8.
- Herezin, V., et al., *Targeting of ECM molecules and their metabolizing enzymes and receptors for the treatment of CNS diseases.* Prog Brain Res, 2014. **214**: p.
 353-88.
- 1104 48. Pimentel, E., *Colony-stimulating factors.* Ann Clin Lab Sci, 1990. **20**(1): p. 36-55.
- 110549.Venet, F., et al., Myeloid cells in sepsis-acquired immunodeficiency. Ann N Y1106Acad Sci, 2021. 1499(1): p. 3-17.
- 110750.Roussel, L. and D.C. Vinh, ICOSL in host defense at epithelial barriers: lessons1108from ICOSLG deficiency. Curr Opin Immunol, 2021. 72: p. 21-26.
- 110951.Panneton, V., et al., Inducible T-cell co-stimulator: Signaling mechanisms in T1110follicular helper cells and beyond. Immunol Rev, 2019. 291(1): p. 91-103.
- Mulcahy, H., et al., *LST1 and NCR3 expression in autoimmune inflammation and in response to IFN-gamma, LPS and microbial infection.* Immunogenetics, 2006. **57**(12): p. 893-903.
- 111453.Heidemann, J., et al., Regulated expression of leukocyte-specific transcript (LST)11151 in human intestinal inflammation. Inflamm Res, 2014. 63(7): p. 513-7.

- 1116 54. Chen, Z., X. Qiu, and J. Gu, *Immunoglobulin expression in non-lymphoid lineage* 1117 *and neoplastic cells.* Am J Pathol, 2009. **174**(4): p. 1139-48.
- 111855.Vettermann, C. and M.S. Schlissel, Allelic exclusion of immunoglobulin genes:1119models and mechanisms. Immunol Rev, 2010. 237(1): p. 22-42.
- 1120 56. Napodano, C., et al., *Mono/polyclonal free light chains as challenging biomarkers* 1121 *for immunological abnormalities.* Adv Clin Chem, 2022. **108**: p. 155-209.
- 112257.Godyna, S., M. Diaz-Ricart, and W.S. Argraves, Fibulin-1 mediates platelet1123adhesion via a bridge of fibrinogen. Blood, 1996. 88(7): p. 2569-77.
- Harikrishnan, K., et al., Cell Derived Matrix Fibulin-1 Associates With Epidermal
 Growth Factor Receptor to Inhibit Its Activation, Localization and Function in
 Lung Cancer Calu-1 Cells. Front Cell Dev Biol, 2020. 8: p. 522.
- 1127 59. Jackson, C.B., et al., *Mechanisms of SARS-CoV-2 entry into cells.* Nat Rev Mol Cell Biol, 2022. **23**(1): p. 3-20.
- 1129 60. Felsenstein, S., et al., *COVID-19: Immunology and treatment options.* Clin 1130 Immunol, 2020. **215**: p. 108448.
- 1131 61. Guizani, I., et al., *SARS-CoV-2 and pathological matrix remodeling mediators*. 1132 Inflamm Res, 2021. **70**(8): p. 847-858.
- 1133 62. Zhang, F., et al., SARS-CoV-2 pseudovirus infectivity and expression of viral entry-related factors ACE2, TMPRSS2, Kim-1, and NRP-1 in human cells from the respiratory, urinary, digestive, reproductive, and immune systems. J Med Virol, 2021. 93(12): p. 6671-6685.
- 113763.DeBruine, Z.J., K. Melcher, and T.J. Triche Jr, Fast and robust non-negative1138matrix factorization for single-cell experiments. bioRxiv, 2021: p. 2021.09.113901.458620.
- 1140 64. Street, K., et al., *Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics.* BMC Genomics, 2018. **19**(1): p. 477.
- 1142 65. Sweeney, R.M. and D.F. McAuley, *Acute respiratory distress syndrome.* Lancet, 2016. **388**(10058): p. 2416-2430.
- 1144 66. Wynn, T.A., *Cellular and molecular mechanisms of fibrosis.* J Pathol, 2008.
 1145 214(2): p. 199-210.
- 1146 67. Turpin, E.A., et al., *Respiratory syncytial virus infection reduces lung*1147 *inflammation and fibrosis in mice exposed to vanadium pentoxide.* Respir Res,
 1148 2010. **11**: p. 20.
- Elewa, Y.H.A., et al., *Histopathological Correlations between Mediastinal Fat- Associated Lymphoid Clusters and the Development of Lung Inflammation and Fibrosis following Bleomycin Administration in Mice.* Front Immunol, 2018. 9: p.
 271.
- 1153 69. Nagata, N., et al., *Features of idiopathic pulmonary fibrosis with organizing pneumonia.* Respiration, 1997. **64**(5): p. 331-5.
- 1155 70. Phan, S.H., *The myofibroblast in pulmonary fibrosis.* Chest, 2002. **122**(6 Suppl):
 p. 286S-289S.
- 1157 71. Ortiz-Zapater, E., et al., *Lung Fibrosis and Fibrosis in the Lungs: Is It All about*1158 *Myofibroblasts*? Biomedicines, 2022. **10**(6).
- 1159 72. Habermann, A.C., et al., Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. Sci Adv, 2020. 6(28): eaba1972.

- 1162 73. Laloglu, E. and H. Alay, *Role of transforming growth factor-beta 1 and connective tissue growth factor levels in coronavirus disease-2019-related lung Injury: a prospective, observational, cohort study.* Rev Soc Bras Med Trop, 2022. 55: p. e06152021.
- 1166 74. Vaz de Paula, C.B., et al., COVID-19: Immunohistochemical Analysis of TGF1167 beta Signaling Pathways in Pulmonary Fibrosis. Int J Mol Sci, 2021. 23(1): p.
 1168 168.
- 1169 75. Fan, T., et al., Discovery of 9O-Substituted Palmatine Derivatives as a New
 1170 Class of anti-COL1A1 Agents via Repressing TGF-beta1/Smads and
 1171 JAK1/STAT3 Pathways. Molecules, 2020. 25(4): p.773.
- 1172 76. Malik, M., et al., Cross-talk between Janus kinase-signal transducer and activator
 1173 of transcription pathway and transforming growth factor beta pathways and
 1174 increased collagen1A1 production in uterine leiomyoma cells. F S Sci, 2020.
 1175 1(2): p. 206-220.
- 117677.Stringer, C., et al., Cellpose: a generalist algorithm for cellular segmentation. Nat1177Methods, 2021. **18**(1): p. 100-106.
- 1178 78. Qi, F., et al., Single cell RNA sequencing of 13 human tissues identify cell types
 1179 and receptors of human coronaviruses. Biochem Biophys Res Commun, 2020.
 1180 526(1): p. 135-140.
- 118179.Sungnak, W., et al., SARS-CoV-2 entry factors are highly expressed in nasal1182epithelial cells together with innate immune genes. Nat Med, 2020. 26(5): p. 681-1183687.
- 118480.Xu, G., et al., The differential immune responses to COVID-19 in peripheral and1185lung revealed by single-cell RNA sequencing. Cell Discov, 2020. 6: p. 73.
- 118681.Zou, X., et al., Single-cell RNA-seq data analysis on the receptor ACE21187expression reveals the potential risk of different human organs vulnerable to11882019-nCoV infection. Front Med, 2020. 14(2): p. 185-192.
- Sounart, H., et al., *Dual spatially resolved transcriptomics for SARS-CoV-2 host- pathogen colocalization studies in humans.* bioRxiv, 2022: p. 2022.03.
 14.484288.
- 1192 83. Pielawski, N., et al., *TissUUmaps 3: Interactive visualization and quality*1193 assessment of large-scale spatial omics data. BioRxiv, 2022. doi:
 1194 https://doi.org/10.1101/2022.01.28.478131.
- 1195 84. Solorzano, L., G. Partel, and C. Wahlby, *TissUUmaps: interactive visualization of*1196 *large-scale spatial gene expression and tissue morphology data.* Bioinformatics,
 1197 2020. **36**(15): p. 4363-4365.
- 119885.Satija, R., et al., Spatial reconstruction of single-cell gene expression data. Nat1199Biotechnol, 2015. **33**(5): p. 495-502.
- 1200 86. Anselin, L., *Local indicators of spatial association—LISA.* Geographical analysis,
 1201 1995. 27(2): p. 93-115.
- 1202

1203 Acknowledgments

1204 We thank members of Drs. Shou-Jiang Gao and Yufei Huang laboratories for 1205 technical assistance and discussions. This study was supported by grants from the 1206 National Institutes of Health (CA096512 and CA124332 to S.-J. Gao), UPMC Hillman 1207 Cancer Center Startup Funds to S.-J. Gao and Y. Huang, and in part by award 1208 P30CA047904. This research was also supported in part by the University of Pittsburgh 1209 Center for Research Computing, RRID:SCR 022735, through the resources provided. 1210 Specifically, this work used the HTC cluster, which is supported by the National Institutes 1211 of Health (S10OD028483).

1212

1213 Author contributions

1214 S.-J. Gao and Y. Huang conceived, designed, supervised and managed the 1215 project. W. Meng, S.R. da Silva and L.P. Chen performed the experiments. G.L. Sica 1216 and W. Meng performed the pathological examination. A. Das, Z.T. Liu, D.M. Hasib, H. 1217 Galloway and Y. Huang developed the computational pipeline and performed the 1218 analyses. A. Das, W. Meng, Z.T. Liu, D.M. Hasib, H. Galloway, S.R. da Silva, L.P. 1219 Chen, Y.F., K.P. Rivera, M. Flores, Y.-C. Chiu, Y. Huang and S.-J. Gao interpreted the 1220 data and participated in the discussions throughout the analysis. A. Paniz-Mondolfi, C. 1221 Bryce, Z. Grimes, E.M. Sodillo and C. Cordon-Cardo obtained the COVID-19 samples. 1222 Y. Huang and S.-J. Gao wrote the manuscript with input from all the authors. All the 1223 authors read, reviewed and approved the manuscript. 1224

1224

1225 Competing interests

1226 The a	uthors declare no	competing interests.
------------	-------------------	----------------------

1228 Data availability

- 1229 The data supporting findings in this study including all the original spatial single-
- 1230 cell transcriptome data, segmented and filtered reads of all cells, and DAPI and H&E
- 1231 staining images will be deposited to Zenodo. The spatial single-cell transcriptome data
- 1232 will also be deposited in GEO.

1233

1234 Code availability

1235 All codes will be available at Zenodo.

1236

1237 Supplementary information

1238 The online version contains supplementary material available at:

1239

1240 **Correspondence and requests for materials** should be addressed to Shou-Jiang Gao

1241 or Yufei Huang.

- 1242 Figure Legend
- 1243 Figure 1: Spatial organization of parenchymal and immune cells in COVID-19 lung 1244 tissues revealed by spatial single-cell transcriptome analysis (SSCTA). A. 1245 Schematic illustration of the spatial single-cell sequencing pipeline used to generate the 1246 target dataset comprised of healthy control (non-COVID-19 tissue, n=1) and COVID-19 1247 tissues (n=5). Samples were hybridized and decoded by sequencing. DAPI and H&E 1248 staining were carried out. All samples were annotated by an expert pathologist (Fig. 1249 S1). B. SSCTA workflow illustrating cell segmentation, cell typing, neighborhood cell-1250 type composition (NCTC) analysis, and tissue pathology analysis. C. Average 1251 expression of cell type markers of all segmented cells across identified cell types in the 1252 SSCTA dataset. D. The UMAP projection of the gene expressions of segmented cells 1253 colored based on cell type, infection, and sample identifier. The UMAP shows negligible 1254 batch differences between the samples. E. Spatial visualization of identified cell types in 1255 two COVID-19 tissues and the non-COVID-19 tissue along with individual spatial plots 1256 illustrating the neighborhood cell type composition of specific cell types. We identified 1257 DAD in all COVID-19 tissues and orderly distribution of major parenchymal cells in non-1258 COVID-19 tissue (PBC-PR). Further plots are provided in Fig. S1. F. Bar plots showing 1259 the percentages of identified cell types and their percentages of SARS-CoV-2 infected 1260 cells.
- 1261

1262 Figure 2: SARS-CoV-2 infection induces global differential gene expression that

1263 mediates pathological damages and inflammation with cell type and spatial

1264 **features. A.** Differential gene expressions between the identified cells in the COVID-19

1265 non-COVID-19 tissue with various conditions are illustrated. The title indicates the 1266 conducted differential expression analysis. Within each row, the bubble size indicates 1267 the -log10 of the corrected p-value and the color indicates the log2 fold change of the 1268 corresponding gene. Each column indicates the different COVID-19 tissues. The first 1269 three panels indicate differential expression analysis between COVID-19 tissues and 1270 non-COVID-19 tissue while the fourth panel indicates the differential expression 1271 analysis between the infected and uninfected cells in the respective COVID-19 tissues. 1272 **B.** Spatial gene expression map of highly expressed CTSL and IGKC. **C.** Spatial gene 1273 expression maps of the rest of the differentially expressed genes. D. Pie chart 1274 illustrating the percentages of cell types in which the genes are expressed in each 1275 tissue. E. Differential expression analysis of COVID-19 tissues compared to non-1276 COVID-19 tissue in cell types that had significant changes in cell numbers based on 1277 Fig. 1F.

1278

1279 Figure 3: Spatial analysis of local SARS-CoV-2 infection rates identifies regions 1280 with high infection rates that match high cell densities, high levels of viral entry-1281 related factors, and localized pathology. A. Spatial distribution of the SARS-CoV-2 1282 infected cells. The spatial visualization of the infection rates revealed infection hotspots 1283 in the COVID-19 tissues. **B.** Moran's I analysis of spatial patterns revealed spatially 1284 distinct high and low infection regions in each COVID-19 tissue. C. Spatial visualization 1285 of the significant local regions identified by Bivariate Moran's I analysis, in which 1286 infection rates and the expressions of TMPRSS2, NRP1, FURIN and ACE2 are spatially 1287 correlated. D. Spatial visualization of the kernel density plot for the cell densities

1288 revealed highly dense cellular hotspots in the COVID-19 samples. E. Spatial 1289 visualization of the significant local regions identified by Bivariate Moran's I analysis, in 1290 which cell densities and the infection regions are spatially correlated, identified as high-1291 density high-infection (HIHD) regions. F. Spatial visualization of the ligand-receptor 1292 coexpression maps for the CSF3-CSF3R pair, which are highly expressed in the high 1293 infection regions. G. Spatial visualization of the significant local regions identified by 1294 Bivariate Moran's I analysis, in which both high infection and high CSF3-CSF3R 1295 coexpression regions are spatially correlated.

1296

1297 Figure 4: Spatial analysis reveals cellular and gene expression features in regions 1298 with high SARS-CoV-2 infection rates. A. A bar plot showing the cell type 1299 composition of all identified cell types in the high and low infection regions. The increase 1300 in alveolar cells (ACs) might suggest the proliferation of ACs due to injury repair of 1301 alveoli and alveoli capillaries and a decrease in epithelial cells (ECs) and vascular 1302 endothelial cells (VECs) might suggest the damages caused by the infection. B. UMAP 1303 projection of the NCTC analysis results of high infection regions (refer to figure 3B) 1304 revealed three distinct clusters out of which two were distinctly enriched in local 1305 compositions of ACs and fibroblasts, which are illustrated on the right with their spatial 1306 visualizations. C. Spatial visualization of the compositions in high infection regions 1307 revealed negative correlation of fibroblasts and ACs (-0.6, Pearson correlation) which 1308 overlapped with annotated OP regions (high fibroblasts, low ACs). D. Differential 1309 expressions of high and low infection regions of the COVID-19 tissues compared to the 1310 non-COVID-19 tissue, which share 18 of the 20 differentially expressed genes,

confirming strong indirect effect of SARS-CoV-2 infection. E. Differential expressions
between the high and low infection regions of the COVID-19 tissues revealed distinct
differentially expressed genes showing upregulation of AC markers SFTPA1 and
SFTPA2 in tissues 1, 3, and 5, and fibroblast markers COL1A1 or COL1A2 in all
COVID-19 tissues. F. Spatial visualization of the spatial gene expression map of
COL1A1 and COL1A2 markers.

1317

1318 Figure 5: Sparse non-negative matrix factorization (SNMF) identifies seven cell 1319 composition signatures that recapitulate different healthy and disease statuses. 1320 A. SNMF revealed seven NCTC signatures which are illustrated in a logo plot. B. 1321 Spatial NCTC signatures visualized after factor loading for each tissue revealed their 1322 associations with normal structures and broad and tissue-specific infection. C. 1323 Trajectory analysis of the cell type compositions with Signatures 1 and 3 generated a 1324 trajectory of reduced normal alveoli and increased immune infiltration from the non-1325 COVID-19 tissue to COVID-19 tissues 1, 4, 3, 5, and 2. The trajectory agrees with the 1326 order of the severity of pathology in the tissues identified in the H&E stained images 1327 (Fig. S1).

1328

Figure 6: Unique cell composition signatures define two separate pathological trajectories. A. The UMAP projection of the Signatures 1 (for non-COVID-19 tissue reference) and Signatures 4-7 recapitulated the severity of pathological progression identified in figure 5C. Two trajectories were derived from the pseudo-progressions of cells defined by these signatures. The trajectories showed a common shared onset T1

1334 and T2 which traverses through Signature 1 "normal-like-alveoli" and Signature 4 "ACs 1335 with MMs infiltration" in T1 and then those enriched by Signature 4 and Signature 5 1336 "VECs with MMs infiltration" in T2. The trajectory then diverged into two paths T3a and 1337 T4a, and T3b and T4b. Path/Trajectory A defined by T3a and T4a progressed through 1338 cells mostly from tissues 3 and 4 enriched in Signature 5 "VEC with MMs infiltration" 1339 ending in Signature 6 "VEC with NK cell infiltration", which was almost exclusively from 1340 tissue 3. Path/Trajectory B defined by T3b and T4b are enriched by Signature 6 in T3b 1341 and Signature 7 "high fibroblasts with MMs infiltration" in T4b. B. UMAP projections of 1342 the five signatures colored based on their individual signature loadings. C. Line plots 1343 illustrating the cell type percentages in band T1, T2, T3(a, b), and T4(a, b). **D.** Spatial 1344 visualization of the cells by cell type in each band is shown along with an identified 1345 representative ROI (red box with dotted lines) for each COVID-19 tissue. Column 7 1346 illustrates the H&E morphology image of the COVID-19 tissues with black dotted lines 1347 highlighting the high infection regions. E. Zoomed-in images of the ROIs selected are 1348 shown. A close examination revealed characteristics of early DAD in T1 and T2, hyaline 1349 membrane, fibrin, lymphocytic infiltration, collapsed alveoli and capillary structure in T3a 1350 and T4a, and edema, increased fibrin, and organizing pneumonia (OP) in T3b and T4b 1351 suggesting a more advanced stage of DAD.

1352

1353 Figure 7: IL6-STAT3 and TGF-β-SMAD2/3 pathways mediate COVID-19 lung

- 1354 **fibrosis and organizing pneumonia. A.** Zoomed in OP region (bottom, red color
- 1355 border) and other non-OP regions (top, black color border) from the H&E image of
- 1356 COVID-19 tissue 1-2C are illustrated. B. Identified cells colored based on the cell types

1357 revealed differences in cell composition signatures between OP and other regions. C. 1358 Bar plot showing an increase in cell density in OP regions compared to other regions. D. 1359 Bar plot showing the percentage of cells per cell type in COVID-19 and non-COVID-19 1360 tissues. There is a decrease in ACs and VECs, and an increase in fibroblasts in the OP 1361 regions of the COVID-19 tissue. An obvious increase in ACs is seen in the non-COVID-1362 19 sample. E. Differential gene expressions between the identified cells in the OP 1363 regions of the COVID-19 tissue sample with cells from the non-COVID-19 tissue and 1364 cells from the other non-OP regions of the same COVID-19 tissue is illustrated. We 1365 observed an upregulation of genes encoding for collagen type I alpha 1 and 2 chains 1366 (COL1A1 and COL1A2) in OP in both tissues compared to the normal tissue or to 1367 regions without OP in the same COVID-19 lung tissues. F. Pie chart illustrating the 1368 percentages of cell types in which the selected genes are expressed in tissues 1 and 2. 1369 **G.** Spatial visualization of differentially expressed genes from figure 7E. The size of the 1370 dots indicates the expression level, and the color indicates the cell type of the cell where 1371 the gene is expressed. **H.** Differential gene expressions between the identified cells in 1372 the OP regions of the COVID-19 tissue with cells from the non-COVID-19 tissue as well 1373 as non-OP regions from the same COVID-19 tissue based on their cell types. Both 1374 COL1A1 and COL1A2 were upregulated in fibroblasts in OP regions compared to 1375 fibroblasts from either normal tissue or non-OP regions from the same tissue. I. The 1376 density plot of the COL1A1 and COL1A2 expressions in OP and other non-OP regions 1377 in COVID-19 tissue samples 1-2C, 2-1A, and non-COVID-19 tissue is illustrated. J. 1378 Examination of the networks associated with the Pulmonary Fibrosis Idiopathic 1379 Signaling Pathways reported by the Ingenuity Pathway Analysis is illustrated. Both IL6-

- 1380 STAT3 and TGF-β-SMAD2/3 pathways mediate the expression of COL1A1 and
- 1381 COL1A2. K. Multi-color IFA staining revealed that cells with a high COL1A1 expression
- 1382 level also had high levels of IL6R α , p-STAT3, TGF- β R2 and SMAD2/3, confirming the
- 1383 activation of these pathways and their potential roles in the upregulation of COL1A1.

1384	Supplemental Information
1385	
1386	Supplemental Tables
1387	Table S1. Gene annotation, cell type markers, and total cells expressing
1388	individual genes and total reads of the individual genes in each lung tissue after
1389	segmentation.
1390	
1391	Table S2. Summary of cell segmentation results.
1392	
1393	Table S3. Summary of cell typing results and SARS-CoV-2 infection status.
1394	
1395	Table S4. Global spatial correlations between local SARS-CoV-2 infection rates
1396	and cell densities by global Moran's I.
1397	
1398	Table S5. Cell composition signatures identified by sparse non-negative matrix
1399	factorization (SNMF).
1400	
1401	Table S6. Spearman correlations of pseudotime Trajectory A versus gene
1402	expressions.
1403	
1404	Table S7. Spearman correlations of pseudotime Trajectory B versus gene
1405	expressions.
1406	

4407	C		
1407	Supp	lementary	rigures

1409	Supplementary Figure 1: Hematoxylin and eosin (H&E) stained images of the five
1410	COVID-19 tissues (1-2C, 2-1A, 3-1A, 4-3B, 5-3B) and the non-COVID-19 tissue (PBC-
1411	PR) along with pathology annotations are illustrated. We observe various degrees of
1412	diffuse alveolar damage (DAD) in the COVID-19 tissues. Tissues 1 and 2 (1-2C and 2-
1413	1A) had prominent organizing pneumonia (OP) while edema, hyaline membrane, and
1414	fibrin clot were prominent in tissues 3, 4, and 5 (3-1A, 4-3B, and 5-3B).
1415	
1416	Supplementary Figure 2: 4',6-diamidino-2-phenylindole (DAPI) staining of all tissues
1417	under study revealed the nuclei location. We used the DAPI-stained images to facilitate
1418	cell nuclei segmentation using the CellPose algorithm.
1419	
1420	Supplementary Figure 3: A. Bar plot showing the total number of reads and the reads
1420 1421	Supplementary Figure 3: A. Bar plot showing the total number of reads and the reads that are segmented to cells using the Baysor algorithm for all tissues under study. We
1421	that are segmented to cells using the Baysor algorithm for all tissues under study. We
1421 1422	that are segmented to cells using the Baysor algorithm for all tissues under study. We segmented ~89%-95% of the reads into cells. B. Bar plot showing the total number of
1421 1422 1423	that are segmented to cells using the Baysor algorithm for all tissues under study. We segmented ~89%-95% of the reads into cells. B. Bar plot showing the total number of segmented cells and the identified cells with a cell-marker read. A total of 1,719,459
1421 1422 1423 1424	that are segmented to cells using the Baysor algorithm for all tissues under study. We segmented ~89%-95% of the reads into cells. B. Bar plot showing the total number of segmented cells and the identified cells with a cell-marker read. A total of 1,719,459
1421 1422 1423 1424 1425	that are segmented to cells using the Baysor algorithm for all tissues under study. We segmented ~89%-95% of the reads into cells. B. Bar plot showing the total number of segmented cells and the identified cells with a cell-marker read. A total of 1,719,459 cells were identified across the tissues.
1421 1422 1423 1424 1425 1426	that are segmented to cells using the Baysor algorithm for all tissues under study. We segmented ~89%-95% of the reads into cells. B . Bar plot showing the total number of segmented cells and the identified cells with a cell-marker read. A total of 1,719,459 cells were identified across the tissues. Supplementary Figure 4: A representative image showing cell boundary polygons of
1421 1422 1423 1424 1425 1426 1427	that are segmented to cells using the Baysor algorithm for all tissues under study. We segmented ~89%-95% of the reads into cells. B. Bar plot showing the total number of segmented cells and the identified cells with a cell-marker read. A total of 1,719,459 cells were identified across the tissues. Supplementary Figure 4: A representative image showing cell boundary polygons of the cells segmented using the Baysor algorithm. Baysor used a binary mask of the

Supplementary Figure 5: Bar plots showing the distribution of the number of
transcripts (reads) that are segmented to each cell. Over 99% of the cells harbored at
least 5-15 reads.

1433

Supplementary Figure 6: Heatmaps illustrating the average expressions of marker
genes in each cell type within each tissue. In all tissues, a total of 18 cell types were
identified including 11 types of parenchymal cells and 7 types of immune cells.

1437

1438 **Supplementary Figure 7:** Uniform Manifold Approximation and Projection (UMAP) of

1439 the gene expressions of individual cells revealed separated clusters for major

1440 parenchymal cells including alveolar cells (ACs) and fibroblasts. By contrast, immune

1441 cells were grouped together and mixed with vascular endothelial cells (VECs) in several

1442 clusters. The poor separation of immune cell types was largely due to highly expressed

1443 Immunoglobulin kappa light chain (IGKC) and Cathepsin L (CTSL) in these cell types,

1444 which is further illustrated in Fig. S8.

1445

Supplementary Figure 8: The UMAP of the gene expressions of all segmented and cell-typed cells across all tissues under study is illustrated in the bottom-right panel. Here, the color of the dots indicates the tissue samples. The rest of the UMAPs illustrate the expressions of different genes colored based on their expression in each cell. We observe that IGKC and CTSL are spread across many clusters, resulting in the poor separation of immune cell types which are mixed with VECs.

1452

1453	Supplementary Figure 9: Spatial visualization of the segmented cells painted based on
1454	their cell types along with the location of the SARS-CoV-2 reads marked with an 'X'.
1455	
1456	Supplementary Figure 10: The neighborhood cell type composition (NCTC) analysis
1457	for COVID-19 tissue 1-2C is illustrated based on the cell type.
1458	
1459	Supplementary Figure 11: The neighborhood cell type composition (NCTC) analysis
1460	for COVID-19 tissue 2-1A is illustrated based on the cell type.
1461	
1462	Supplementary Figure 12: The neighborhood cell type composition (NCTC) analysis
1463	for COVID-19 tissue 3-1A is illustrated based on the cell type.
1464	
1465	Supplementary Figure 13: The neighborhood cell type composition (NCTC) analysis
1466	for COVID-19 tissue 4-3B is illustrated based on the cell type.
1467	
1468	Supplementary Figure 14: The neighborhood cell type composition (NCTC) analysis
1469	for COVID-19 tissue 5-3B is illustrated based on the cell type.
1470	
1471	Supplementary Figure 15: The neighborhood cell type composition (NCTC) analysis
1472	for non-COVID-19 tissue PBC-PR is illustrated based on the cell type.
1473	
1474	Supplementary Figure 16: Spatial visualization of regions with blood vessels revealed
1475	the lining of VECs along the vessels together with other vessel-associated cells

including ACs, fibroblasts and smooth muscle cells (SMCs). Each dot indicates a cell,and the color of each dot indicates the cell type.

1478

1479 **Supplementary Figure 17:** Spatial visualization of a representative region with

1480 bronchioles revealed the lining of epithelial cells (ECs), smooth muscle cells (SMCs)

1481 and VECs along the bronchiole together with other bronchiole-associated cells including

ACs and fibroblasts. Each dot indicates a cell, and the color of each dot indicates thecell type.

1484

1485 **Supplementary Figure 18:** Spatial visualization of the expressions of the 19

1486 dysregulated genes in different cell types and their tissue distributions in COVID-19

1487 tissue 1-2C are illustrated. We observe significant variations in the expression patterns

1488 suggesting their complex involvements in different aspects of SARS-CoV-2 infection

and COVID-19 lung pathology. The color of each dot indicates the cell type, and the

1490 size indicates their expression level.

1491

Supplementary Figure 19: Spatial visualization of the expressions of the 19
dysregulated genes in different cell types and their tissue distributions in COVID-19
tissue 2-1A are illustrated. We observe significant variations in the expression patterns
suggesting their complex involvements in different aspects of SARS-CoV-2 infection
and COVID-19 lung pathology. The color of each dot indicates the cell type, and the
size indicates their expression level.

1498

Supplementary Figure 20: Spatial visualization of the expressions of the 19
dysregulated genes in different cell types and their tissue distributions in COVID-19
tissue 3-1A are illustrated. We observe significant variations in the expression patterns
suggesting their complex involvements in different aspects of SARS-CoV-2 infection
and COVID-19 lung pathology. The color of each dot indicates the cell type, and the
size indicates their expression level.

1505

Supplementary Figure 21: Spatial visualization of the expressions of the 19
dysregulated genes in different cell types and their tissue distributions in COVID-19
tissue 4-3B are illustrated. We observe significant variations in the expression patterns
suggesting their complex involvements in different aspects of SARS-CoV-2 infection
and COVID-19 lung pathology. The color of each dot indicates the cell type, and the
size indicates their expression level.

1512

Supplementary Figure 22: Spatial visualization of the expressions of the 19 dysregulated genes in different cell types and their tissue distributions in COVID-19 tissue 5-3B are illustrated. We observe significant variations in the expression patterns suggesting their complex involvements in different aspects of SARS-CoV-2 infection and COVID-19 lung pathology. The color of each dot indicates the cell type, and the size indicates their expression level.

1519

1520 **Supplementary Figure 23:** Spatial visualization of the expressions of the 19

1521 dysregulated genes in different cell types and their tissue distributions in non-COVID-19

1522 tissue PBC-PR are illustrated. We observe significant variations in the expression

1523 patterns suggesting their complex involvements in different aspects of SARS-CoV-2

1524 infection and COVID-19 lung pathology. The color of each dot indicates the cell type,

1525 and the size indicates their expression level.

1526

Supplementary Figure 24: Bubble plots of cell-type specific differential expression
analysis of the high infection versus the low infection regions of the same COVID-19
tissues is illustrated. The analysis further confirmed the upregulation of SFTPA1 or
SFTPA2 in ACs and COL1A2 in fibroblasts in infected tissues. Within each row, the

bubble size indicates the -log10 of the corrected p-value and the color indicates the log2

1532 fold change of the corresponding gene.

1533

Supplementary Figure 25: Box plots of signature loadings for each identified signature
 generated by the SNMF decomposition of NCTC vectors are illustrated.

1536

1537 Supplementary Figure 26: A. Heatmap illustrating the Spearman correlation of the 1538 pseudotime scores of Trajectory A and the gene expression. **B.** Heatmap illustrating the 1539 Spearman correlation of the pseudotime scores of Trajectory B and the gene 1540 expression. **C.** Heatmap illustrating the Spearman correlation of the pseudotime scores 1541 of Trajectory A and the ligand-receptor co-expression values of each cell. D. Heatmap 1542 illustrating the Spearman correlation of the pseudotime scores of Trajectory B and the 1543 ligand-receptor co-expression values of each cell. In all plots, deeper red indicates a 1544 high positive correlation and deeper blue indicates a high negative correlation. We also

apply a p-value threshold (p-values<0.5) to remove the genes with lesser correlationsand the removed genes are painted white to indicate no correlation.

1547

1548 Supplementary Figure 27: Analysis of COVID-19 and IPF single-cell RNA-seq

1549 datasets. A. UMAP projections showing expression of COL1A1 and COL1A2, paired

1550 with fibroblast and myofibroblast cell subtypes from single-cell RNA-seq COVID-19

1551 tissue atlas. Violin plots showing expression of COL1A1 and COL1A2 in cells from

1552 COVID-19 patients. B. GSEA enrichment of myofibroblasts in cells ranked by

1553 expressions of COL1A1 and COL1A2 from the single-cell COVID-19 tissue atlas with a

1554 resulting p-value < 0.001. The significant enrichment and the large number of highly

1555 ranked hits indicate that most myofibroblasts from the single-cell COVID-19 tissue atlas

1556 have high expressions of COL1A1 and COL1A2. **C.** UMAP projections showing

1557 expressions of COL1A1 and COL1A2 next to UMAP of fibroblast cell subtypes from

1558 single-cell RNA-seq pulmonary fibrosis dataset. Violin plots showing expressions of

1559 COL1A1 and COL1A2 in IPF and control patients. The UMAPs and violin plots only

1560 represent cells from IPF patients or control. **D.** GSEA enrichment of myofibroblast in

1561 cells from IPF and control donors ranked by expressions of COL1A1 and COL1A2 with

a resulting p-value < 0.001. The significant enrichment and high correlation between the

1563 myofibroblast cell type and high expressions of COL1A1 and COL1A2 indicate that


1564 most myofibroblasts from the single-cell pulmonary fibrosis dataset have high


1565 expressions of COL1A1 and COL1A2. E. A heatmap showing expressions of


1566 significantly differentially expressed genes from the 'IPF High' run in cells with high and


1567 low expressions of COL1A1 and COL1A2. F. A heatmap showing expressions of

1568 significantly differentially expressed genes from the 'IPF Diagnosis' cells with high and 1569 low expressions of COL1A1 and COL1A2. G. GSEA enrichment of significantly 1570 differentially expressed genes from the 'IPF Diagnosis' run against significantly 1571 differentially expressed genes ordered by fold change from the 'IPF High' run with a 1572 resulting p-value < 0.001. The high enrichment of upregulated genes and 1573 downregulated genes from the 'IPF Diagnosis' run in the 'IPF High' run indicates that 1574 the two differential expression analyses are capturing similar expression patterns. H. A 1575 heatmap showing expression of differentially expressed genes in cells with high and low 1576 COL1A1 and COL1A2 expressions from the single-cell COVID-19 dataset. I. GSEA 1577 enrichment of significantly differentially expressed genes from the 'IPF High' run in 1578 significantly differentially expressed genes from the COVID-19 dataset with a resulting 1579 p-value < 0.001. The high ranking of the 'IPF High' genes indicates that similar genes 1580 co-express with COL1A1 and COL1A2 in both COIVID-19 and IPF when considering 1581 IPF and control samples. J. GSEA enrichment of differentially expressed genes from 1582 'IPF Diagnosis' against differentially expressed genes from the 'COVID High' run 1583 ordered by fold change with a resulting p-value < 0.001. The high ranking of the 'IPF 1584 Diagnosis' genes indicates that the genes that co-express with COL1A1 and COL1A2 in 1585 COVID-19 have similar co-expression patterns in IPF. K. Top 10 enriched pathways 1586 from IPA pathway analysis for the differentially expressed genes from the COVID-19 1587 single-cell RNA-seg dataset.













Figure 5



Broad immune infiltration

2e-06

3e-06

4e-06

1e-06

0

Figure 6







Figure 7






2-1A




3-1A

1-2C

4-3B













Figure S3














5-3B

PBC-PR




Figure S10 - Sample 1-2C Spatial Map of Cell Types




Figure S11 - Sample 2-1A Spatial Map of Cell Types




Figure S12 - Sample 3-1A Spatial Map of Cell Types




Figure S13 - Sample 4-3B Spatial Map of Cell Types




Figure S14 - Sample 5-3B Spatial Map of Cell Types






Figure S15 - Sample PBC-PR Spatial Map of Cell Types








Figure S18: 1-2C





Figure S19: 2-1A









Figure S20: 3-1A














Figure S23: PBC-PR









lonocytes







T cells

.

.

IGKC

FOXP3

ICOSLG

IFITM2

ICAM1

ARG1

SFTPA1

CLDN5

CXCR6


C1QA


FUT4


1-2C 2-1A 3-1A 4-3B 5-3B


CD40LG

CoV-2










<u>.</u>...

FUT4

1-2C 2-1A 3-1A 4-3B 5-3B


JCHAIN




2-1A 3-1A


1-2C

4-3B 5-3B












2-1A

5-3B







egulated 🛛 📕 No change

Table S1. Gene annotation, cell type markers, and total cells expressing individual genes and total reads of the individual genes in each lung tissue after segment:

		-						-		-			•
	Sample name		2C		1 A		1A		3B		3B		C-PR
Gene HGNC ID Name	Annotation of Cell Typ		(Total R) 80341										
A2M HGNC:7 alpha-2-macroglobulin ACE2 HGNC:1355 angiotensin I converting enzyme 2		213	221			9830 1274	1310	667	694	3353	3471	50795 176	83748 178
ACKR HGNC:4035 atypical chemokine receptor 1 (Duffy blood)	g Vascular endothelial ce					3307	3428		2729		10555		
ACTA: HGNC:130 actin alpha 2, smooth muscle	Smooth muscle cells	5164	6156	9006	9442	4110	4296	6756				14003	
AGER HGNC:320 advanced glycosylation end-product specific	Alveolar cells		27549			4034						17701	
AGRP HGNC:330 agouti related neuropeptide AIRE HGNC:360 autoimmune regulator		406 196	427 200	2963 1116	3067 1130	1601 660	1655 671	1154 549	1208 566	5717 1506	5966 1539	499 321	523 333
AP1S; HGNC:560 adaptor related protein complex 1 subunit s	igma 2	926	962		1166	806	832	591	609	2509	2570	1954	2042
APOE HGNC:613 apolipoprotein E	0	12592	17576		27036	6671		22642		7374	7863	5771	6545
ARG1 HGNC:663 arginase 1	Macrophages and mon		399	5884	6076	1952	2018	1534	1594	5139	5357	322	332
ASCL1 HGN C:738 achaete-scute family bHLH transcription factor ASCL2 HGN C:740 achaete-scute family bHLH transcription factor		404	418	3640	3738	1531		1713	1793	3938	4080	301	308
ASCLE HGNC:740 achaete-scute family bHLH transcription factor BATFE HGNC:2891 basic leucine zipper ATF-like transcription factor		320 541	333 553	1475 2619	1544 2671	1194 1098	1254 1118	588 983	604 1013	1717 2611	1768 2673	203 437	217 446
BPIFB HGNC:1610 BPI fold containing family B member 1	Epithelial cells	94	98	333	352	337	348	196	216	1188	1296	81	83
C1QA HGNC:1241 complement C1q A chain	Macrophages and mon											6548	7757
C1QB HGNC:1242 complement C1q B chain	Macrophages and mon											5310	5947
C2 HGNC:1248 complement C2 C3 HGNC:1318 complement C3		738 5183	783 6047	896 3892	927 4086	497 1834	515 2012	548 2738	576 2956	1156 4882	1211 5191	291 2884	305 3135
C4BP HGNC:1325 complement component 4 binding protein	alpha	382	402	1406	1452	650	668	475	487	1589	1642	704	735
CAV1 HGNC:1527 caveolin 1		3742	3999	1940	2007	1098	1129	1671	1737	5318	5526	11368	12788
CCL1 HGNC:1061 C-C motif chemokine ligand 17		249	261	1159	1246	1024	1083	424	447	1566		300	311
CCL2 HGNC:1061 C-C motif chemokine ligand 2		1131	1237 795	4239 938	4377	1970	2072	589			12757	1651	
CCL5 HGNC:1063 C-C motif chemokine ligand 5 CCL8 HGNC:1063 C-C motif chemokine ligand 8		758 254	270	938 1143	961 1161	995 578	1024 595	537 403	554 417	1338 2857	1396 3001	493 146	510 149
CCR2 HGNC:1603 C-C motif chemokine receptor 2		2594		19388		8426	8872	7505			31621	3473	3643
CCR4 HGNC:1605 C-C motif chemokine receptor 4		408	425	4728	4880	2670	2808	1730	1809	6289	6509	491	507
CCR5 HGNC:1606 C-C motif chemokine receptor 5		1710		12777		4988	5223	4221			16525	1685	1767
CCR6 HGNC:1607 C-C motif chemokine receptor 6 CCR7 HGNC:1608 C-C motif chemokine receptor 7		136 577	142 597	1197 2161		661 1791	682 1853	428 630	442 654	1195 3593	1223 3686	206 565	212 579
CD14 HGNC:1628 CD14 molecule	Macrophages and mon			1668	1700	1539	1575	759	782	2163	2197	498	514
CD16 HGNC:1631 CD163 molecule	Macrophages and mon			6400	6949	3026	3275	3698	4010		10817	1383	1488
CD19 HGNC:1633 CD19 molecule	B cells	761	785	10762	11125	3179	3273	3477	3608	8204	8483	576	590
CD1C HGNC:1636 CD1c molecule	Dendritic cells	3239		4063	4182		3760	3177	3294	3550	3629	1215	1249
CD20 HGNC:1641 CD209 molecule GYPA HGNC:4702 glycophorin A (MNS blood group)	Eryth ro cyte	384 161	401 169	1780 2335	1826 2409	1131 1410	1172 1447	717 462	736 477	2537 3642	2620 3775	399 101	410 102
CD27 HGNC:1763 CD274 molecule	Liyanooya	237	241	1010	1023	498	505	413	429	1149	1175	192	198
CD28 HGNC:1653 CD28 molecule		257	266	2219	2310	1178	1238	792	821	2634	2731	287	297
CD30 HGNC:2887 CD300e molecule		266	269	942	969	639	654	713	733	1574	1612	191	200
CD34 HGNC:1662 CD34 molecule CD3D HGNC:1673 CD3d molecule	Vascular endothelial ce T cells	3195 1154	3371 1216	4713 5081	4856 5261	2423 3234	2511 3360	2047 2383	2132 2496	5684 8192	5884 8618	5157 1223	5513 1282
CD3E HGNC:1674 CD3e molecule	T cells	451	464		1177	860	879	383	388	1567	1599	603	618
CD3G HGNC:1675 CD3g molecule	T cells	44	44	109	109	16	16	17	17	54	54	61	61
CD4 HGNC:1678 CD4 molecule	T cells	9244		32619								6899	7329
CD40 HGNC:1191 CD40 molecule CD40 HGNC:1193 CD40 ligand		1284 785	1323	6802 12160		2935 6193	3042 6460	2489 3159	2584	9651 25458	10041	1100 633	1128 663
CD44 HGNC:1681 CD44 molecule (Indian blood group)		3032		4303			2369	2170			13517	5280	5692
CD68 HGNC:1693 CD68 molecule	Macrophages and mon	6117	6731	15311	16792	12141	13295	8779	9502	27401	30488	6359	7170
CD7 HGNC:1695 CD7 molecule		645	676				2005	1387		3516	3618	455	470
CD79 HGNC:1698 CD79a molecule CD79 HGNC:1699 CD79b molecule	B cells	1664 1428		21479 4402		6222	6448 3286	4727 2752	4911 2877	15235 6391	15962 6771	800 1968	842 2061
CD79 HGNC:1709 CD796 molecule	B cells	653	676	3873	3981	3115 3291	3383		1652	5186	5335	514	534
CD83 HGNC:1703 CD83 molecule		562		3093	3184	1163	1202	1034	1077	3142	3256	666	692
CD86 HGNC:1705 CD86 molecule		1		6	6	5	5	6	6	7	7	4	4
CD8A HGNC:1706 CD8a molecule	T cells	690		3340	3433	2467	2550	943	971	3632	3738	515	534
CD8B HGNC:1707 CD8b molecule CEAC, HGNC:1820 CEA cell adhesion molecule 8	T cells Granulocytes	177 592	182 623	638 12368	653 12895	684 5524	710 5723	236 2825	247 2937	762 15840	788 16754	173 477	182 493
CFP HGNC:8864 complement factor properdin	Glandrocytes	249	259	866	886	522	537	253	259	836	857	168	172
CFTR HGNC:1884 CF transmembrane conductance regulator	lonocytes	76	78	664	685	362	372	315	318	935	948	88	92
CLDN HGNC:2047 claudin 5	Vascular endothelial ce												
CLEC1 HGNC:1691 C-type lectin domain containing 10A CLEC5 HGNC:2054 C-type lectin domain containing 5A		1432 155		13952 606	14589 618	8036 561	8443 567	4628 330			19859 1225	1189 249	1257 255
CLECS HGNC:2670 C-type lectin domain containing 9A	Dendritic cells	87	89		1337	761	796	326	337	1788		132	139
COL1 HGNC:2197 collagen type I alpha 1 chain	Fibroblasts		10687			4084	4627				32237		
COL1 HGNC:2198 collagen type I alpha 2 chain	Fibroblasts		26898			7678	8625					20266	
COL6 HGNC:2211 collagen type VI alpha 1 chain	Cranula aut	4358			7095	4101	4285	4035			16919		
CPA3 HGNC:2298 carboxypeptidase A3 CR1 HGNC:2334 complement C3b/C4b receptor 1 (Knops blo	Granulocytes	172 149		784 535	830 551	528 552	540 567	334 266	352 273	1152 924	1190 960	536 177	568 183
CSF3F HGNC:2439 colony stimulating factor 3 receptor	see Proubl	1207		4135		2462	2652	2288	2417	5857	6299	978	1027
CTSB HGNC:2527 cathepsin B		7288	8303	13176	14716	6499	7033				22099	6933	7722
CTSL HGNC:2537 Cathepsin L		88357		2E+05			4E+05					59979	
CX3C HGNC:2558 C-X3-C motif chemokine receptor 1		2180 503	2289 515	4816 2813	4977 2887	5229 2280	5456 2352	3811 1265	3979 1305	6462 5770	6702 6047	2088 581	2175 615
CXCL: HGNC:1063 C-X-C motif chemokine ligand 10 CXCL: HGNC:1664 C-X-C motif chemokine ligand 16		925	960		2887		1560	1265	1305	3750	3860	1436	
CXCL: HGNC:1923 C-X-C motif chemokine ligand 17		244	253	1440	1465	781	803	443	453	2546	2644	416	429
CXCL: HGNC:4603 C-X-C motif chemokine ligand 2		433	459	406	415	498	514	474	484	1440	1501	2463	2681

					0.2.4	600	707	200	200	4070	4207	200	24.0
CXCL! HGNC:1064 C-X-C motif chemokine ligand 5			124	802	821	690	707	380	390	1272		300	318
CXCLI HGNC:6025 C-X-C motif chemokine ligand 8			513	6944	7172	2635	2737	2163	2224	7876	8142	593	612
CXCL! HGNC:7098 C-X-C motif chemokine ligand 9			989	1887	1962	962	994	366	379	2635	2831		1327
CXCR HGNC:6027 C-X-C motif chemokine receptor 2	3	84 4	400	1190	1233	1065	1097	660	680	1723	1785	351	361
CXCR HGNC:4540 C-X-C motif chemokine receptor 3	15	80 16	652 1	13483	14118	7375	7700	3969	4144	15472	16266	1170	1219
CXCR HGNC:2561 C-X-C motif chemokine receptor 4	4	09 4	426	447	453	430	435	363	368	907	927	677	705
CXCR HGNC:1060 C-X-C motif chemokine receptor 5	12	62 12	299 2	22082	23246	6761	6969	4409	4551	26834	28867	608	619
CXCR HGNC:1664 C-X-C motif chemokine receptor 6	17	06 18	803 1	18547	19774	7365	7789	7532	8136	14835	15713	886	911
CYP2I HGNC:2632 cytochrome P450 family 2 subfamily F member 1	1	26 1	131	580	585	359	365	233	238	742	755	148	148
DDX5 HGNC:1910 DExD/H-box helicase 58	3	48 3	351	970	975	704	723	468	478	2246	2293	398	408
	oth muscle cells 21		251	6468	6681	4351	4512	2619		11073		3562	4077
EDN1 HGNC:3176 endothelin 1				1213	1232	810	824	654		3617		2183	2341
EOME HGNC:3372 eomesodermin				12299		6617	6955	3231		21051		619	644
				1318	1362	756	781	686		1665		566	584
EREG HGNC:3443 epiregulin			152	900	952	696	726	412	435	1556		222	234
F13A: HGNC:3531 coagulation factor XIII A chain			586	2258	2430	1186	1244	773	816	2851		467	484
FABP HGNC:3559 fatty acid binding protein 4		44	46	565	576	347	356	226	232	724	742	241	254
FBLN: HGNC:3600 fibulin 1		60 181				3117	3539	7320				11966	
FCGR: HGNC:3613 Fc fragment of IgG receptor Ia			136	452	455	186	188	82	82	317	320	60	62
FCGR: HGNC:3616 Fc fragment of IgG receptor IIa			953	4115	4245	2500	2572	1171	1201	6552		986	1026
FCGR: HGNC:3618 Fc fragment of IgG receptor IIb				1164	1200	842	858	487	507	1804		442	456
FCGR: HGNC:3620 Fc fragment of IgG receptor IIIb	27		890	5795	5991	2908	3009	1843	1929		10392	1547	1656
FKBP: HGNC:1862 FKBP prolyl isomerase 11	17	64 18	864 1	10293	10777	10756	11504	4846	5096	20117	21717	1634	1706
FOLR: HGNC:3793 folate receptor beta	10	84 11	129	1803	1837	1177	1206	792	814	2267	2311	661	679
FOXI1 HGNC:3815 forkhead box I1 Iono	cytes 4	09 4	428	3688	3804	1886	1963	1337	1384	4358	4513	343	354
FOXJ1 HGNC:3816 forkhead box J1 Ciliat	ed cells	3	3	3	3	3	3	2	2	18	18		
FOXN HGNC:2139 forkhead box N4	1	23 1	128	489	503	432	437	228	238	624	645	138	141
FOXP HGNC:6106 forkhead box P3 T cell	s 27	43 28	853 2	24051	25729	6922	7186	4868	5058	13528	14139	2291	2367
FURIN HGNC:8568 furin, paired basic amino acid cleaving enzyme	21	31 22	233 1	10658	11076	4796	4976	5064	5313	14298	14921	2722	2845
FUT4 HGNC:4015 fucosyltransferase 4	9	69 10	012 1	15533	16926	7541	8103	2887	3034	19700	21747	886	917
•			779			1402		832	848		3506	790	812
GATA: HGNC:4172 GATA binding protein 3			350				1231	701	713	3269	3374	329	338
CSF3 HGNC:2438 colony stimulating factor 3	65					16965						4914	5203
GJA5 HGNC:4279 gap junction protein alpha 5					15272	6626	6995	5248		26618		3351	3669
GNLY HGNC:4219 gap junction protein arpha 5	40			5564	5748	2419	2498	1598	1676	7443		622	671
				444									
GPR1 HGNC:3128 G protein-coupled receptor 183			159		455	547	560	266	276	663	680	238	248
				1094		949	972	679		2015		418	431
GZMK HGNC:4711 granzyme K	23					18686		7559		66279		1577	1632
HLA-E HGNC:4944 major histocompatibility complex, class II, DQ beta				1267	1335	790	823	970	1015		1507	1331	1423
HLA-E HGNC:4954 major histocompatibility complex, class II, DR beta			799	3451	3546	2105	2175	1457	1492	4225	4382	597	621
HPGD HGNC:1789 hematopoietic prostaglandin D synthase		91	92	470	486	495	514	208	214	673	697	169	172
ICAM HGNC:5344 intercellular adhesion molecule 1			710	7157	7385	2243	2313	2848	2976	6938	7172	2268	2381
ICOS HGNC:5351 inducible T cell costimulator	2	01 2	202	1277	1310	586	601	384	401	1182	1213	210	215
ICOSL HGNC:1708 inducible T cell costimulator ligand	29	01 30	035 3	32600	35066	12841	13580	12265	13179	27279	29152	2238	2328
IDO1 HGNC:6059 indoleamine 2,3-dioxygenase 1	6	40 E	583	965	986	777	802	637	668	5481	5824	337	361
IFIH1 HGNC:1887 interferon induced with helicase C domain 1	4	21 4	434	728	743	433	446	373	380	1621	1670	424	435
IFITM HGNC:5413 interferon induced transmembrane protein 2	80	12 85	583 1	16017	16883	7018	7363	9795	10406	28790	31093	8062	8677
IFITM HGNC:5414 interferon induced transmembrane protein 3	164	52 185	575 1	17428	18617	8998	9577	19021	21300	64561	77842	12481	13753
IFNA2 HGNC:5423 interferon alpha 2		33	33	314	326	281	293	133	135	450	458	58	60
IFNB1HGNC:5434 interferon beta 1	1	39 1	143	1292	1319	641	656	431	453	1382	1421	134	136
IFNE HGNC:1816 interferon epsilon			57	258	264	185	188	98	102	210	219	57	57
IFNG HGNC:5438 interferon gamma			555	4161	4328	3203	3374	1638	1713	5996	6342	357	372
IFNGF HGNC:5439 interferon gamma receptor 1				1465	1496	724	744	1654	1711	3837	3974	3034	3194
IFNGF HGNC:5440 interferon gamma receptor 2				1920	1983	932	959	879	916	3236		1227	1273
IGKC HGNC:5716 immunoglobulin kappa constant	748					55923							
IGLL5 HGNC:3847 immunoglobulin lambda like polypeptide 5	20		543	7002	7721	4199	4514	3505		11634		1240	1439
IL10 HGNC:5962 interleukin 10		79 ZU	81	385	388	209	211	193	199	395	401	72	75
IL10 HGNC:5965 interleukin 10 receptor subunit beta			871	5833	6008	3274	3368	2142	2241		10091	979	1033
							3308 1966				5080		
IL17A HGNC:5981 interleukin 17A			391	4253	4397	1900		956	979	4913		290	297
IL1A HGNC:5991 interleukin 1 alpha			501	6524	6789	2731	2864	1406	1468	7135	7411	392	403
IL1B HGNC:5992 interleukin 1 beta			735	3369		1390	1419	1180	1226	3375	3448	448	458
IL2 HGNC:6001 interleukin 2			131	2079				735	767	2614	2702	159	163
IL22 HGNC:1490 interleukin 22			278	3039	3120	1750	1813	1074	1115		3090	232	239
IL27 HGNC:1915 interleukin 27			249	2350	2411	924	950	798	819	2139	2190	185	191
IL2RA HGNC:6008 interleukin 2 receptor subunit alpha	23	46 24	431 1	10989	11338	3998	4103	4454	4625	12931	13390	1482	1532
IL33 HGNC:1602 interleukin 33	1	97 1	199	394	399	218	221	176	180	620	635	369	384
IL3RA HGNC:3563 interleukin 3 receptor subunit alpha	9	46 9	982	5462	5666	2165	2228	1478	1530	6942	7183	1201	1246
IL4 HGNC:6014 interleukin 4	4	73 4	491	3969	4146	1787	1862	1503	1577	3354	3519	319	325
IL5 HGNC:6016 interleukin 5	3	43 3	355	1668	1720	964	987	578	592	1304	1355	289	299
IL6 HGNC:6018 interleukin 6	3	19 3	333	1430	1471	1062	1094	527	546	4160	4399	1266	1381
IL6R HGNC:6019 interleukin 6 receptor	5	54 5	573	3306	3366	1139	1155	1114	1146	2536	2600	685	717
IL6ST HGNC:6021 interleukin 6 signal transducer				1378	1415	632	649	685	709	3566	3700	2331	2450
IL7 HGNC:6023 interleukin 7			297	1906	1950	1214		802	827	2714	2797	338	350
IL7R HGNC:6024 interleukin 7 receptor			920	4640	4800	1612	1653	2247	2367	3929	4051	2181	2327
				1323	1387	924	959	1260	1323		3408	5878	6438
IRF4 HGNC:6119 interferon regulatory factor 4			921	4295	4375		1623	1110	1134		3509	454	464
ISG15 HGNC:4053 ISG15 ubiquitin like modifier				7142	7480	4105	4337	4103		15226		1369	1443
			949	1519	1546	1110	1130	1644	1706	2850	2930	730	765
ITLN1 HGNC:1825 intelectin 1				2774		1509		741	766			248	251
	2	50 Z	200	2114	2040	1203	1044	141	700	3233	JJ/0	240	271

JCHAI HGNC:5713 joining chain of multimeric IgA and IgM			21499			6728	7953	2628		19176		1454	3375
KIT HGNC:6342 KIT proto-oncogene, receptor tyrosine kinase		482	499	978	996	730	757	464	480	2147			2278
KLRB: HGNC:6373 killer cell lectin like receptor B1		311	329	1521		888	906	608	625	1945		304	317
KLRC: HGNC:6375 killer cell lectin like receptor C2	NK cells	131	137	484	499	494	502	323	339	675	695	129	133
KLRD: HGNC:6378 killer cell lectin like receptor D1	NK cells	536	562	4258	4482	1868	1931	986	1020	5417	5665	443	456
KRT1: HGNC:6415 keratin 13		184	202	880	902	534	549	396	411	1116	1158	112	113
KRT1 HGNC:6416 keratin 14	Basal cells	265	270	2960	3028	1472	1513	746	768	3546	3641	278	288
KRT1! HGNC:6421 keratin 15		840	901	5259	5485	2733	2867	1606	1684	6785	7147	537	553
KRT1! HGNC:6436 keratin 19		4295	5157	7262	7681	4066	4336	2867	3044	17270	20219	3220	3432
	Basal cells	186	213	589	602	588	705	275	288	3127		112	113
LEF1 HGNC:6551 lymphoid enhancer binding factor 1	busul cells	214	220	1782			1238	522	544	3048		603	630
LGR6 HGNC:1971 leucine rich repeat containing G protein-coupl	od recentor 6	499	516	3062			1696	1002	1054		3296	431	448
					1636	827	850			1548			
LILRA HGNC:1550 leukocyte immunoglobulin like receptor A4		206	210					568				173	176
LST1 HGNC:1418 leukocyte specific transcript 1		5422								72496		4255	4509
LTF HGNC:6720 lactotransferrin		147	161	1482		767	795	322		2419		136	137
LYVE1 HGNC:1468 lymphatic vessel endothelial hyaluronan rece	Lymphatic endothelial	336	352	608	625	308	317	214	221	376	385	740	786
CSF1 HGNC:2432 colony stimulating factor 1		514	528	1226		474	479	314	320	1096	1113	344	348
MGP HGNC:7060 matrix Gla protein		9428	10545	34860	38829	10408	10997	6878	7373	22754	24270	10835	11935
MKI6 HGNC:7107 marker of proliferation Ki-67		61	62	180	183	191	194	70	71	348	359	59	61
MRC1 HGNC:7228 mannose receptor C-type 1		1143	1197	5250	5446	2179	2227	1635	1693	6191	6375	1428	1522
MS4A HGNC:7315 membrane spanning 4-domains A1	B cells	132	133	1053	1067	709	725	400	406	1693	1727	110	114
	Granulocytes	299	305	3172	3266	1674	1714	833	857	4015	4129	401	414
	Mesothelial cells	1191	1294	3928	4078	1435	1474	913	964	3332			1799
MUC1 HGN C:7508 mucin 1, cell surface associated		955	1021	662	686	638	663	579	609	2614			1189
	Epithelial cells	145	158	799	827	453	462	502	528	987		152	157
, , , , , , , , , , , , , , , , , , , ,	•				14781								
	Epithelial cells	1310						4319		24767		853	878
MX1 HGNC:7532 MX dynamin like GTPase 1		1579	1638		7514		2877	3514		11341			1471
	NK cells	6110								58792			3515
NKG7 HGNC:7830 natural killer cell granule protein 7		1352				1060		837		2043		758	818
NRP1 HGNC:8004 neuropilin 1		4267	4523					2922		11280		4047	4282
PAX5 HGNC:8619 paired box 5		270	277	2099	2158	1711	1760	566		3210		253	264
PCSK: HGNC:1730 proprotein convertase subtilisin/kexin type 1	inhibitor	4234	4500	18102	19090	9788	10407	9194	9843	17936	18870	3926	4233
PDCD HGNC:8760 programmed cell death 1		5017	5317	14253	14860	11119	11612	6214	6484	10882	11277	2413	2483
PECAI HGNC:8823 platelet and endothelial cell adhesion molecu	Vascular endothelial ce	538	551	452	458	308	313	527	533	1013	1028	1484	1525
PF4 HGNC:8861 platelet factor 4		271	309	733	751	584	605	393	424	706	729	94	95
PLAC: HGNC:1925 placenta associated 8		1599	1703	9248		4682		2901			12703	1279	1329
PLIN2 HGNC:248 perilipin 2		741	766	5024					1869			939	976
PPAR HGNC:9236 peroxisome proliferator activated receptor gam	ma	582	602	4635					1814	7013		1229	1305
PRF1 HGNC:9360 perforin 1	ind	672	690	2647	2784		1595	1416	1495	3888	4107	538	551
•	Macrophagos and man		1483	2925					2081	4697	4919		4252
	Macrophages and mon								5019	8072		2408	4232 2577
PTN HGNC:9630 pleiotrophin		2909	3202										
PTPRI HGN C:9666 protein tyrosine phosphatase receptor type C		1938	2015	4054 7065			3133 3607			6289	6473	1931	2026
RETN HGNC:2038 resistin		779		/065	7348	3445				0520	10010	745	
S100, HGNC:1049 S100 calcium binding protein A8			811					2932			10016	715	746
		3361	4237	4766	5142	3103	3395	1839	2036	8888	10537	500	553
SCGB: HGNC:1252 secretoglobin family 1A member 1	Epithelial cells	3361 1865	4237 4537	4766 5388	5142 6536	3103 2592	3395 3999	1839 2288	2036 2948	8888 9280	10537 16352	500 1106	553 3020
	Epithelial cells Epithelial cells		4237	4766	5142 6536	3103 2592	3395	1839	2036	8888 9280 2634	10537 16352 2825	500 1106	553
	•	1865	4237 4537	4766 5388	5142 6536	3103 2592	3395 3999	1839 2288	2036 2948	8888 9280	10537 16352	500 1106	553 3020
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A	•	1865 534	4237 4537 645	4766 5388 1572	5142 6536 1622	3103 2592 1012	3395 3999 1054 372	1839 2288 904	2036 2948 988	8888 9280 2634	10537 16352 2825	500 1106 1687	553 3020 2580
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2	Epithelial cells	1865 534 72	4237 4537 645 73 1805	4766 5388 1572 733 3864	5142 6536 1622 749 3996	3103 2592 1012 364	3395 3999 1054 372 1990	1839 2288 904 245	2036 2948 988 253 2160	8888 9280 2634 886 5024	10537 16352 2825 914 5260	500 1106 1687 139	553 3020 2580 142 2057
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1	Epithelial cells Alveolar cells	1865 534 72 1690	4237 4537 645 73 1805 8052	4766 5388 1572 733 3864 10922	5142 6536 1622 749 3996	3103 2592 1012 364 1901 7860	3395 3999 1054 372 1990 9860	1839 2288 904 245 2040 6527	2036 2948 988 253 2160 8187	8888 9280 2634 886 5024	10537 16352 2825 914 5260 44290	500 1106 1687 139 1957	553 3020 2580 142 2057
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2	Epithelial cells Alveolar cells Alveolar cells	1865 534 72 1690 6106 4370	4237 4537 645 73 1805 8052 5125	4766 5388 1572 733 3864 10922 10027	5142 6536 1622 749 3996 14182	3103 2592 1012 364 1901 7860 4643	3395 3999 1054 372 1990 9860 5192	1839 2288 904 245 2040 6527 4322	2036 2948 988 253 2160 8187 4783	8888 9280 2634 886 5024 24407 14103	10537 16352 2825 914 5260 44290 17992	500 1106 1687 139 1957 18841	553 3020 2580 142 2057 29304 8821
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells	1865 534 72 1690 6106 4370	4237 4537 645 73 1805 8052 5125	4766 5388 1572 733 3864 10922 10027 16766	5142 6536 1622 749 3996 14182 11632 21268	3103 2592 1012 364 1901 7860 4643 8284	3395 3999 1054 372 1990 9860 5192 10209	1839 2288 904 245 2040 6527 4322 16532	2036 2948 988 253 2160 8187 4783 26081	8888 9280 2634 886 5024 24407 14103 16118	10537 16352 2825 914 5260 44290 17992 19624	500 1106 1687 139 1957 18841 7456	553 3020 2580 142 2057 29304 8821 74526
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC1E HGNC:1093 solute carrier family 18 member A2	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes	1865 534 72 1690 6106 4370 25948 217	4237 4537 645 73 1805 8052 5125 69259 223	4766 5388 1572 733 3864 10922 10027 16766 2954	5142 6536 1622 749 3996 14182 11632 21268 3056	3103 2592 1012 364 1901 7860 4643 8284 1801	3395 3999 1054 372 1990 9860 5192 10209 1871	1839 2288 904 245 2040 6527 4322 16532 795	2036 2948 988 253 2160 8187 4783 26081 834	8888 9280 2634 886 5024 24407 14103 16118 4400	10537 16352 2825 914 5260 44290 17992 19624 4559	500 1106 1687 139 1957 18841 7456 35495 291	553 3020 2580 142 2057 29304 8821 74526 299
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC1E HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells	1865 534 72 1690 6106 4370 25948 217 345	4237 4537 645 73 1805 8052 5125 69259 223 356	4766 5388 1572 733 3864 10922 10027 16766 2954 1388	5142 6536 1622 749 3996 14182 11632 21268 3056 1411	3103 2592 1012 364 1901 7860 4643 8284 1801 915	3395 3999 1054 372 1990 9860 5192 10209 1871 931	1839 2288 904 245 2040 6527 4322 16532 795 764	2036 2948 988 253 2160 8187 4783 26081 834 792	8888 9280 2634 886 5024 24407 14103 16118 4400 1926	10537 16352 2825 914 5260 44290 17992 19624 4559 1979	500 1106 1687 139 1957 18841 7456 35495 291 1234	553 3020 2580 142 2057 29304 8821 74526 299 1285
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC12 HGNC:1080 sourfactant family 18 member A2 TAGL1 HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes	1865 534 72 1690 6106 4370 25948 217 345 1202	4237 4537 645 73 1805 8052 5125 69259 223 356 1252	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703	5142 6536 1622 749 3996 14182 11632 21268 3056 1411 5876	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711	1839 2288 904 245 2040 6527 4322 16532 795 764 2502	2036 2948 988 253 2160 8187 4783 26081 834 792 2590	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523	500 1106 1687 139 1957 18841 7456 35495 291 1234 971	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC11 HGNC:1093 solute carrier family 18 member A2 TAGL! HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes	1865 534 72 1690 6106 4370 25948 217 345 1202 1562	4237 4537 645 73 1805 8052 5125 69259 223 356 1252 1650	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 2225	5142 6536 1622 749 3996 14182 11632 21268 3056 1411 5876 2276	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC1E HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404	4237 4537 645 73 1805 8052 5125 69259 223 356 1252 1650 10363	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 2225 22628	5142 6536 1622 749 3996 14182 11632 21268 3056 1411 5876 2276 24172	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC18 HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin TBX2: HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151	4237 4537 645 73 1805 8052 5125 69259 223 356 1252 1650 10363 153	4766 5388 1572 733 3864 10027 16766 2954 1388 5703 2225 22628 622	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 2276 24172 634	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743 186	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC1& HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1597 tumor protein p63	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82	4237 4537 645 73 1805 5125 69259 223 356 1252 1650 10363 153 88	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 2225 22628 622 413	5142 6536 1622 749 3996 14182 11632 21268 3056 1411 5876 2276 24172 634 449	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544 401	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743 186 140	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188 150	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987 583	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197 60	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC1& HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1597 tumor protein p63 TPPP: HGNC:2416 tubulin polymerization promoting protein fac	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Ciliated cells	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484	4237 4537 645 73 1805 5125 69259 223 356 1252 1650 10363 153 88 1763	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 2225 22628 622 413 4075	5142 6536 1622 749 3996 14182 11632 21268 3056 1411 5876 2276 24172 634 449 4233	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544 401 1767	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743 186 140 2161	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188 150 2474	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987 583 7902	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197 60 1962	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC18 HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1159 T-box transcription factor 21 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1597 tumor protein p63 TPPP: HGNC:2416 tubulin polymerization promoting protein fai TPSAE HGNC:1201 tryptase alpha/beta 1	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Ciliated cells Granulocytes	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484 4307	4237 4537 645 73 1805 8052 5125 69259 223 356 1252 1650 10363 153 88 1763 5425	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 2225 22628 622 413 4075 3784	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 2276 24172 634 449 4233 3908	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630 2953	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544 401 1767 3162	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743 186 140 2161 4152	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188 150 2474 4676	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056 6304	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987 583 7902 6736	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197 60 1962 3633	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064 4261
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC1& HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1597 tumor protein p63 TPPP: HGNC:2416 tubulin polymerization promoting protein fac	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Ciliated cells Granulocytes	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484	4237 4537 645 73 1805 5125 69259 223 356 1252 1650 10363 153 88 1763	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 2225 22628 622 413 4075	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 2276 24172 634 449 4233 3908 2640	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630 2953 1472	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544 401 1767 3162 1517	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743 186 140 2161	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188 150 2474	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987 583 7902	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197 60 1962	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC18 HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1159 T-box transcription factor 21 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1597 tumor protein p63 TPPP: HGNC:2416 tubulin polymerization promoting protein fai TPSAE HGNC:1201 tryptase alpha/beta 1	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Ciliated cells Granulocytes 2	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484 4307	4237 4537 645 73 1805 8052 5125 69259 223 356 1252 1650 10363 153 88 1763 5425	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 22258 622 413 4075 3784 2553	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 2276 24172 634 449 4233 3908 2640	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630 2953	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544 401 1767 3162 1517	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743 186 140 2161 4152	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188 150 2474 4676	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056 6304	10537 16352 2825 914 5260 44290 17992 4559 1979 7523 3965 20485 987 583 7902 6736 2673	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197 60 1962 3633	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064 4261
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC12 HGNC:1080 surfactant protein C SLC12 HGNC:1155 transgelin TBX2: HGNC:1155 transgelin TBX2: HGNC:1157 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1597 tumor protein p63 TPPP: HGNC:2416 tubulin polymerization promoting protein fai TPSAE HGNC:1776 triggering receptor expressed on myeloid cells TRPM HGNC:1432 transient receptor potential cation channel su	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Ciliated cells Granulocytes 2	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484 4307 1367	4237 4537 645 73 1805 8052 5125 69259 223 356 1252 1650 10363 153 88 1763 5425 1428	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 22258 622 413 4075 3784 2553	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 2276 24172 634 449 4233 3908 2640	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630 2953 1472	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544 401 1767 3162 1517	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743 186 140 2161 4152 1370	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 1280 11645 188 150 2474 4676 1424 665	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056 6304 2609	10537 16352 2825 914 5260 44290 17992 4559 1979 7523 3965 20485 987 583 7902 6736 2673 2467	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197 60 1962 3633 481	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064 4261 500
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC12 HGNC:1080 surfactant protein C SLC12 HGNC:1155 transgelin TBX2: HGNC:1155 transgelin TBX2: HGNC:1157 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1597 tumor protein p63 TPPP: HGNC:2416 tubulin polymerization promoting protein fai TPSAE HGNC:1776 triggering receptor expressed on myeloid cells TRPM HGNC:1432 transient receptor potential cation channel su	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Granulocytes 2 Brush cells Ciliated cells	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484 4307 1367 298	4237 4537 645 73 1805 5125 69259 223 356 1252 1650 10363 153 88 1763 5425 1428 307 956	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 2225 22628 622 4015 3784 2553 3784 2553 2062 599	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 2276 24172 634 449 4233 3908 2640 2103	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630 2953 1472 1322 512	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544 401 1767 3162 1517 1362	1839 2288 904 245 2040 6527 4322 795 764 2502 1231 10743 186 140 2161 4152 1370 644	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188 150 2474 4676 1424 665 397	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056 6304 2609 2399	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987 583 7902 6736 2673 2467 1668	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197 60 1962 3633 481 394	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064 4261 500 409
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC18 HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1297 tumor protein p63 TPPP: HGNC:2116 transforming receptor expressed on myeloid cells TREM HGNC:1776 triggering receptor expressed on myeloid cells TRPM HGNC:1432 transient receptor potential cation channel su TUBB- HGNC:2077 tubulin beta 4B class IVb	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Granulocytes 2 Brush cells Ciliated cells	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484 4307 1367 298 912	4237 4537 645 73 1805 5125 69259 223 356 1252 1650 10363 153 88 1763 5425 1428 307 956	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 2225 22628 622 4015 3784 2553 3784 2553 2062 599	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 2276 24172 634 449 4233 3908 2640 2103 617 15209	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630 2953 1472 1322 512	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544 401 1767 3162 1517 1362 524 6243	1839 2288 904 245 2040 6527 4322 795 764 2502 1231 10743 186 140 2161 4152 1370 644 391 6699	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188 150 2474 4676 1424 665 397	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056 6304 2609 2399 1620 15054	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987 583 7902 6736 2673 2467 1668 15909	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197 60 1962 3633 481 394 982	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064 4261 500 409 1009
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC18 HGNC:1093 solute carrier family 18 member A2 TAGL HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1597 tumor protein p63 TPPP: HGNC:2416 tubulin polymerization promoting protein fai TPSAE HGNC:176 triggering receptor expressed on myeloid cells TRPM HGNC:1432 transient receptor potential cation channel su TUBB: HGNC:2244 transmembrane immune signaling adaptor TYR	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Granulocytes 2 Brush cells Ciliated cells	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484 4307 1367 298 912 6913	4237 4537 645 73 1805 5125 69259 223 356 1252 1650 10363 153 88 1763 5425 1428 307 956 7616	4766 5388 1572 733 3864 10922 10027 16766 2954 1388 5703 2225 22628 622 413 4075 3784 2553 2062 599 14347	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 2276 24172 634 449 4233 3908 2640 2103 617 15209	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630 2953 1472 1322 512 5989	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 544 401 1767 3162 1517 1362 524 6243	1839 2288 904 245 2040 6527 4322 795 764 2502 1231 10743 186 140 2161 4152 1370 644 391 6699	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188 150 2474 4675 1424 665 397 7191	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056 6304 2609 2399 1620 15054	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987 583 7902 6736 2673 2467 1668 15909	500 1106 1687 139 1957 18841 7456 35495 291 1234 971 2271 6563 197 60 1962 3633 481 394 982 7053	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064 4261 500 409 1009 8452
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC18 HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin TBX2: HGNC:1155 transgelin TBX2: HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1597 tumor protein p63 TPPP: HGNC:2101 tryptase alpha/beta 1 TREM HGNC:1201 tryptase alpha/beta 1 TREM HGNC:176 triggering receptor expressed on myeloid cells TRPM HGNC:1244 transmembrane immune signaling adaptor TM VIM HGNC:1269 vimentin WT1 HGNC:1279 WT1 transcription factor	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Granulocytes 2 Brush cells Ciliated cells	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484 4307 1367 298 912 6913 930 62	4237 4537 645 73 1805 5125 69253 356 1252 1650 10363 153 88 1763 5425 14307 956 7616 975 65	4766 5388 1572 733 3864 10922 10766 2954 1388 5703 2225 22628 622 413 4075 3784 2553 2053 2599 14347 3069 245	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 2276 24172 634 449 4233 3908 2640 2610 3617 15209 3156 246	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630 2953 1472 1322 512 5989 3152 307	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 401 1767 3162 1517 1362 1517 2524 6243 3282 316	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743 186 140 2161 4152 1370 6699 1261 138	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 11645 188 150 2474 4676 1426 5397 7191 1305 141	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056 6304 2609 2399 1620 15054 2791 455	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987 583 7902 6736 2673 2467 1668 15909 2868 460	500 1106 1687 139 1957 18841 7456 291 1234 971 2271 6563 197 60 1962 3633 481 3982 7053 847 70	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064 4261 500 409 1009 8452 873 73
SCGB: HGNC:1839 secretoglobin family 3A member 2 SEMA HGNC:1072 semaphorin 3A SFTA2 HGNC:1838 surfactant associated 2 SFTPA HGNC:1079 surfactant protein A1 SFTPA HGNC:1079 surfactant protein A2 SFTPC HGNC:1080 surfactant protein C SLC18 HGNC:1093 solute carrier family 18 member A2 TAGLI HGNC:1155 transgelin TBX2: HGNC:1159 T-box transcription factor 21 TGFB1 HGNC:1176 transforming growth factor beta 1 TMPR HGNC:1187 transmembrane serine protease 2 TNF HGNC:1189 tumor necrosis factor TP63 HGNC:1297 tumor protein p63 TPPP: HGNC:2416 tubulin polymerization promoting protein fai TPSAE HGNC:176 triggering receptor expressed on myeloid cells TRPM HGNC:1244 transmembrane immune signaling adaptor TYF VIM HGNC:1269 vimentin	Epithelial cells Alveolar cells Alveolar cells Alveolar cells Alveolar cells Granulocytes Smooth muscle cells Basal cells Granulocytes 2 Brush cells Ciliated cells	1865 534 72 1690 6106 4370 25948 217 345 1202 1562 9404 151 82 1484 4307 1367 298 912 6913 930	4237 4537 645 73 1805 8052 5125 69223 356 1252 1650 10363 153 88 1763 5425 1428 307 956 7616 975	4766 5388 1572 733 3864 10922 16766 2954 1388 5703 2225 22628 622 413 4075 3784 2553 2062 599 14347 3069 245 2331	5142 6536 1622 749 3996 14182 21268 3056 1411 5876 22776 24172 634 449 4233 3908 2640 2103 617 15209 3156 2460 2400	3103 2592 1012 364 1901 7860 4643 8284 1801 915 3600 1735 23341 529 376 1630 2953 1472 1322 5989 3152 307 862	3395 3999 1054 372 1990 9860 5192 10209 1871 931 3711 1770 25544 401 1767 3162 1517 1362 524 6243 3282 316 885	1839 2288 904 245 2040 6527 4322 16532 795 764 2502 1231 10743 186 140 2161 4152 1370 644 391 6699 1261 138 1504	2036 2948 988 253 2160 8187 4783 26081 834 792 2590 1280 1280 1280 1280 1280 1280 1424 665 397 7191 1305 141 1571	8888 9280 2634 886 5024 24407 14103 16118 4400 1926 7273 3875 19259 972 549 7056 6304 2609 2399 1620 15054 2791 455	10537 16352 2825 914 5260 44290 17992 19624 4559 1979 7523 3965 20485 987 583 7902 6736 2673 2467 1668 15909 2868 460 11957	500 1106 1687 139 1957 18841 7456 291 1234 971 2271 6563 197 60 1962 3633 481 3982 7053 847 70	553 3020 2580 142 2057 29304 8821 74526 299 1285 1004 2374 7089 203 61 2064 4261 500 409 1009 8452 873 73

Table S2. Summary of cell segmentation results

Sample name	1-2C	2-1A	3-1A	4-3B	5-3B	PBC-PR	Total
Total Reads	1,137,704	2,380,636	1,441,118	1,161,277	3,424,675	869,453	10,414,863
Number of Genes	222	222	222	222	222	221	
Total Segmented Reads	1,074,491	2,224,394	1,339,792	1,112,148	3,231,976	773,102	9,755,903
Percentages of Segmented Reads (%)	94.44381	93.43696	92.96893	95.7694	94.37322	88.9182	93
Total Cells	186,659	406,963	276,676	227,585	470,294	151,282	1,719,459
Total Cells with Cell Type Marker Gene	137,260	317,259	193,293	163,431	369,042	126,531	1,306,816
Percentages of Cells with Cell Type Marker Gene (%)	73.53516	77.9577	69.86258	71.81097	78.47049	83.63916	
Total Cells after Filtering	67,701	196,221	87,701	74,843	287,832	62,674	776,972
Average Transcripts per Cell	5.756469	5.465852	4.842476	4.886758	6.87226	5.110371	

Table S3. Summary of cell typing results and SARS-CoV-2 infection status																			
Sample Name	Alveola	Macroph	Fibrobla	Vascula	T cells	Granulo	B cells	Dendriti	Epithelia	Smooth	NK cells	Ciliated	lonocyte	Basal ce	Mesothe	Brush ce	Lympha	Erythroc	Total
1-2C Number of Cells	19111	14470	10097	8621	2936	2165	1831	1695	1622	1612	1574	969	275	209	199	142	118	55	67701
Cell Type Percentage(%)	28.229	21.373	14.914	12.734	4.3367	3.1979	2.7045	2.5037	2.3958	2.3811	2.3249	1.4313	0.4062	0.3087	0.2939	0.2097	0.1743	0.0812	100
Number of infected Cells	336	179	152	115	51	32	20	19	30	29	26	23	6	4	2	1	1	0	690
Infected Cell Percentage (%	1.7581	1.237	1.5054	1.334	1.7371	1.4781	1.0923	1.1209	1.8496	1.799	1.6518	2.3736	2.1818	1.9139	1.005	0.7042	0.8475	0	0.0102
2-1A Number of Cells	28,779	40357	25625	16635	13360	9856	20629	3120	12470	3392	11793	2792	2113	2018	957	1038	222	1065	167442
Cell Type Percentage (%)	14.667	20.567	13.059		6.8086		10.513	1.59		1.7287	6.0101	1.4229	1.0768	1.0284	0.4877	0.529	0.1131	0.5428	100
Number of infected Cells	501	660	350	301	309	210	653	49	228	66	258	56	30	50	14	17	4	15	3771
Infected Cell Percentage (%	1.7409	1.6354	1.3659	1.8094	2.3129	2.1307	3.1654	1.5705	1.8284	1.9458	2.1877	2.0057	1.4198	2.4777	1.4629	1.6378	1.8018	1.4085	0.0225
3-1A Number of Cells	11,240	16820	4498	15384	5699	4882	6073	2212	5766	1882	8064	1285	1189	1126	332	584	118	547	87,701
Cell Type Percentage (%)	12.816	19.179	5.1288	17.541	6.4982	5.5666	6.9247	2.5222		2.1459	9.1949	1.4652	1.3557	1.2839	0.3786	0.6659	0.1345	0.6237	100
Number of infected Cells	363	224	91	276	97	66	131	31	83	43	112	24	17	14	2	8	2	7	1591
Infected Cell Percentage (%	3.2295	1.3317	2.0231	1.7941	1.7021	1.3519	2.1571	1.4014	1.4395	2.2848	1.3889	1.8677	1.4298	1.2433	0.6024	1.3699	1.6949	1.2797	0.0181
4-3B Number of Cells	17,337	15485	4825	10434	4132	3179	4698	1931	3683	1974	4080	1278	689	459	183	259	60	157	74,843
Cell Type Percentage (%)	23.164	20.69	6.4468	13.941	5.5209	4.2476	6.2771	2.5801	4.921	2.6375	5.4514	1.7076	0.9206	0.6133	0.2445	0.3461	0.0802	0.2098	100
Number of infected Cells	402	267	96	209	94	67	144	32	80	50	90	26	21	9	6	5	3	1	1602
Infected Cell Percentage (%	2.3187	1.7242	1.9896	2.0031	2.2749	2.1076	3.0651	1.6572	2.1721	2.5329	2.2059	2.0344	3.0479	1.9608	3.2787	1.9305	5	0.6369	0.0214
5-3B Number of Cells	42,922	50411	40691	24428	17326	15181	20224	4651	24242	8788	21432	5747	2828	4558	929	1435	147	1892	######
Cell Type Percentage (%)	14.912	17.514	14.137	8.4869	6.0195	5.2743	7.0263	1.6159	8.4223	3.0532	7.446	1.9967	0.9825	1.5836	0.3228	0.4986	0.0511	0.6573	100
Number of infected Cells	978	1319	893	768	501	443	524	135	705	258	840	130	89	108	46	33	3	66	7839
Infected Cell Percentage (%	2.2786	2.6165	2.1946	3.1439	2.8916	2.9181	2.591	2.9026	2.9082	2.9358	3.9194	2.262	3.1471	2.3695	4.9516	2.2997	2.0408	3.4884	0.0272
PBC-Number of Cells	27378	5719	9465	7717	1491	1638	1173	736	1262	3290	629	922	139	159	185	145	199	29	62276
Cell Type Percentage (%)	43.962	9.1833	15.198	12.392	2.3942	2.6302	1.8836	1.1818	2.0265	5.2829	1.01	1.4805	0.2232	0.2553	0.2971	0.2328	0.3195	0.0466	100

Table S4. Global spatial correlations between local SARS-CoV-2 infection ratesand cell densities by global Moran's I.

Sample name	1-2C	2-1A	3-1A	4-3B	5-3B
Coefficient (r)	0.325	0.636	0.287	0.248	0.078

	Normal-like Alveoli	Bronchile	Broad immune infiltration	ACs w/ MM infiltration	VECs w/ MM infiltration	VECs w/ NK infiltration	, High fibroblasts w/ MM
n-Alveolar	0.5643179	0.0121138	0	0.6477053	0.0404455	0	0.0336691
n-B	0.0177815	0	0.2864881	0.0001489	0.0357681	0.0298888	0.0017179
n-Basal	0	0.1029554	0.0025063	0	0	0.0135613	0
n-Brush	0	0	0.0019199	0	0	0.0032618	0
n-Ciliated	0.0105512	0.1403089	0.002555	0.002187	0.0131246	0	0.0055952
n-Dendritic	0.0076009	0.006494	0.0079063	0.0128054	0.0373424	0.0272293	0
n-Epithelial	0	0.6141461	0.0867002	0.0092846	0	0.1219462	0
n-Erythrocyte	0	0.0014696	0.0023376	0	0	0.0068894	0
n-Fibroblasts	0.1193691	0	0	0	0.031177	0	0.7342991
n-Granulocytes	0.0125711	0.0494878	0.0963014	0.0253557	0.0136434	0.1360229	0.0080645
n-lonocytes	0	0	0.0145924	0	0.0018038	0.0202377	0
n-Lymphatic	0	0	0	0	0	0	0
n-Macrophages	0	0.0162048	0.2233146	0.2728252	0.4667314	0	0.1577208
n-Mesothelial	0	0	0	0	0	0	0
n-NK	0	0.0066883	0.0999384	0.0296879	0	0.3184191	0.0179067
n-Smooth	0.0529362	0.0501313	0	0	0.0099377	0.0428492	0.0410268
n-T	0.0294544	0	0.17544	0	0.0869477	0.0040867	0
n-Vascular	0.1854178	0	0	0	0.2630784	0.2756075	0

Table S6. S	Spearman Co	rrelations of		e Trajectory	A versus G	ene Express	sions	
Gene	ACs	VECs		MMs	NK cells	T cells	B cells	Granulocytes
A2M	-0.2765578	-0.285168	-0.238348	-0.182516	-0.229521	-0.249141	-0.223907	-0.2508999
ACE2			0.043395			0.061204		
ACTA2	-0.1070443	-0.084294	-0.149374	-0.054684				-0.07261664
AGER	-0.0464048	-0.124302			-0.069421			
AGRP								-0.06517783
AIRE			0.044831					
AP1S2		-0.085735						
APOE		-0.057446		-0.164077	-0.089098	-0.054176	-0.12528	-0.08344893
ARG1			0.046766	0.063714			0.044833	
ASCL1								-0.0473939
BATF3								0.044194834
C1QA				-0.078339				
C1QB	0.0867708		0.059652					0.061753909
C2				-0.045239			-0.042925	
C3		-0.045129		0.0.0200	-0.076592	-0.048363	-0.043823	
CAV1	-0.1734009		-0 157273	-0 090972		-0.05613	-0.11769	-0.12119816
CCL17	0.175 1005	0.100 100	0.107270	0.050572	0.120001	0.0635	0.117.05	0.12119010
CCL2					-0.052658	0.0000		
CCL5					0.052050	0.04699		
CCR2			0.051705			0101000		
CCR5			0.054213					
CCR6			0.00 1220					0.045881367
CD163				-0.046732				-0.04655853
CD19	0.0438856			0.010/02				0.01000000
CD274	0.0 100000							-0.04879447
CD28						0.059283		0.046970801
CD34	-0.0782965	-0.120828	-0.099378		-0.071386			
CD3E							0.0501	
CD4			0.046742		-0.046078	-0.086732		
CD40			0.056504		-0.052999			
CD40LG	0.0655237	0.058233	0.046805			0.069183		0.06671726
CD44	-0.0692463			-0.0675			-0.048534	-0.07242388
CD68					0.053609			0.061876787
CD7			0.053738					
CD79A	0.061052							
CD79B							-0.075542	
CD80			0.058972		0.05314			0.074283622
CD8A			0.049234	0.054959		0.070571		0.063172204
CD8B						0.052538		
CEACAM8	0.0634125		0.063658					0.211105625
CFP								0.043873213
CLDN5		-0.080936	-0.055542			-0.065148		-0.0632258
CLEC10A	0.080319	0.050673	0.050981	0.06959		0.070331		
	0.000010	0.000000	0.00001	2.30303		0.0.001		

CLEC5A								-0.04331821
COL1A1	-0.0434716		0.095684			-0.044134		
COL1A2	-0.1288032	-0.077353					-0.071241	-0.04643754
COL6A1						-0.051441		
CPA3						-0.04277		-0.05276376
CSF3	0.0825488	0.055434	0.057477					
CTSB				-0.123315	-0.066372	-0.06243	-0.049898	
CTSL	0.1555903	0.134861	0.082006	0.109746		0.064454	0.060173	0.142779746
CX3CR1							-0.04356	
CXCL16				-0.050227				
CXCL2	-0.0819782	-0.070601	-0.074434		-0.052996	-0.047334	-0.056277	
CXCL5							0.043694	
CXCL9						-0.047127		
CXCR2						0.045496		0.057255351
CXCR3	0.0534724	0.073938	0.07601	0.04483	0.082672			0.091774059
CXCR5	0.0936446	0.055021	0.10011	0.055826			0.073588	0.056048048
CXCR6	0.0586824		0.093284	0.043907				0.051339988
DES			-0.052901					
EDN1	-0.0567181	-0.047026	-0.05669			-0.053867		-0.0593376
EOMES	0.0643587			0.055331		0.069938		0.046845356
FBLN1	-0.0936202	-0.097959	-0.109604	-0.048301	-0.086736	-0.063898		-0.09633971
FCGR1A						-0.04277		
FCGR3B				-0.04382	-0.047063			0.050848563
FKBP11	0.0833244	0.078857		0.078018	0.069366		0.075718	0.049317294
FOXI1	0.0456297	0 07 47 6	0.050640	0.04740		0.054020		0.049750788
FUT4	0.0546642	0.07476	0.050612	0.04718		0.054029		
GATA2						-0.044676		
GJA5 GYPA					-0.058265		0.055007	
GZMK	0.1124151	0 11247	0.113746		0.067483	0 12106		0.116377053
ICOS	0.1124151	0.11247	0.115740	0.090550	0.007483	0.12190	0.077254	0.110377055
ICOSLG	0 0800651	0 080021	0.100679		0.066888			
IDO1	0.0890031	0.000021	0.100079		-0.04533			
IFIH1			-0.042804		0.04000			
IFITM2	-0.0499703	-0 066448	0.042004			-0.066731	-0.057621	-0.09603561
IFITM3	0.0499703	-0.111749		-0.052976	-0 138866		-0.07538	
IFNG	0.0564185		0.066231		01200000	01102000	0.07000	01121/0002
IFNGR1			-0.072411		-0.063603	-0.043599		-0.07228366
IFNGR2		-0.053552						
IGKC	0.1358517	0.110124	0.130462					
IL10RB						0.043795	0.050399	
IL17A	0.0427097							
IL1A	0.0579209	0.045525	0.048089			0.052517		
IL1B					-0.042758	-0.046179		
IL1R1						-0.045698	-0.066127	-0.04663377

IL2			0.043067					
IL22		0.046282						
IL27			0.045304					
IL2RA	0.047885					-0.048032		
IL33								-0.04506483
IL3RA						-0.042991		
IL4		0.046986				0.052446		
IL6			-0.0546					-0.05910199
IL6R						-0.042505		
IL6ST	-0.0570582					-0.066205		
INMT	-0.1212277	-0.066216	-0.147888				-0.053286	
ISG15	0.0567547							0.053995743
ITLN1								0.056264167
JCHAIN	0.0478496	0.045442	0.054362					-0.04797501
KIT	-0.0677552	-0.08017	-0.05075					-0.04424782
KLRC2								0.045877299
KLRD1					-0.04341			
KRT13						-0.048733		0.045118996
KRT15						-0.04434		
KRT19						-0.043261		
LEF1							0.042944	
LGR6							0.044754	
LST1	0.11908	0.137493	0.077651	0.07928		0.073122	0.047908	0.08865345
LTF						0.047044		
MGP	-0.0431061	-0.054076						-0.07369367
MKI67								0.052051356
MRC1				-0.048254				
MS4A2								0.092534008
MSLN			-0.04623					-0.04534354
MUC1						-0.057608		0.045367682
MUC5B	0.0802862	0.056127						
NCAM1	0.1151786	0.04776	0.103537	0.097938	0.077103			0.090689078
NKG7					-0.068881			
NRP1	-0.0589314	-0.070173	-0.050651	-0.061653	-0.08547		-0.050626	
PCSK1N				0.043314		0.04325		-0.06915208
PDCD1				0.043172	0.045251			
PECAM1	-0.0425713	-0.084631	-0.04948					
PF4					-0.049737			
PLAC8					0.045747			
PPARG					0.073269			
PRG4	-0.0611091		-0.080717	-0.065106				-0.06883645
PTN					-0.046331			
PTPRC								-0.09296068
RETN			0.067828			0.056703		
S100A8			0.059619				-0.046239	

SCGB3A2							-0.043726	
SFTA2	0.0711606							
SFTPA1	-0.0912305		-0.063382	-0.05158				
SFTPA2			-0.050218		-0.044033		-0.047493	
SFTPC	-0.1716209	-0.117223	-0.088311	-0.104805	-0.057423	-0.082973	-0.097653	-0.11385289
SLC18A2			0.074543			-0.04352		
TAGLN			-0.04517					
TBX21							0.07757	
TGFB1		-0.048865	-0.050631	-0.043419			-0.056812	
TMPRSS2	0.0450597	0.063989		0.058446	0.105499		0.055832	
TPPP3								-0.04383628
TPSAB1								-0.28480969
TUBB4B			-0.04293					
TYROBP				-0.132481			-0.074625	-0.06259818
VIM			0.047509					
WT1							0.047543	

Table S7. S	Spearman C	orrelations	of Pseudoti	me Trajecto	ory B versus	Gene Expr	ressions	
Gene	ACs	VECs	rivioviasi	MMs	NK cells	T cells	B cells	Granulocytes
A2M	-0.23417	-0.18242	-0.18695	-0.11699	-0.07008	-0.13915	-0.11668	-0.199064005
ACE2						0.047165		
ACKR1		0.048854					-0.04833	
ACTA2	-0.09122	-0.10498	-0.09113			-0.04457		
AGER	-0.0654	-0.12614	-0.04869					
AGRP	0.049945							
AP1S2	-0.04246	-0.07303					-0.04535	
APOE				-0.07856		-0.03913		
ARG1	0.047952					0.046863		
ASCL1								-0.037819398
BATF3						0.037658		
C1QA	0.058691							0.09027356
C1QB	0.117966	0.054073	0.089102	0.096327			0.058879	0.125662283
C3								-0.063321455
CAV1	-0.15927	-0.18698	-0.14654	-0.07419	-0.07115	-0.05335	-0.04429	-0.103846221
CCL2						0.056462		0.041291612
CCR2	0.06541	0.063104		0.046706		0.038923		0.045579992
CCR4		0.05497	0.03879					
CCR5	0.06756			0.037975	0.051752			
CCR6					0.045262			
CD163								0.037295985
CD19	0.060925	0.040203	0.041826				0.044888	
CD34	-0.0689	-0.09669	-0.06878		-0.0509			
CD4	0.049011							
CD40	0.039212						0.058188	
CD40LG	0.107726	0.077691		0.045761		0.08453		0.068746563
CD44	-0.05332				0.052098			-0.050139472
CD68				-0.07668				
CD7						0.052587		
CD79A	0.08843		0.042754				0.092262	
CD79B							-0.12707	0.047044000
CD83							0 0 0 0 0 4 5	0.047211302
CD8A	0.007000						0.038345	0.04.404.04.04
CEACAM8	0.067966						0.055024	0.214210161
CFTR	0.0001	0 00001	0 00000			0 10 12	0.054296	0.070252260
CLDN5	-0.0661	-0.08001	-0.08032	0 057002		-0.1043	-0.05523	-0.079253269
CLEC10A	0.068948	0.065709	0.055969	0.057083	0.050440	0.074607	0 062025	
COL1A1 COL1A2	-0.08054		0.238038 0.074501		0.050449		0.063025	-0.043885551
COLIAZ CPA3	-0.06054		0.074501			-0.0388	0.000741	-0.043885551
CPA3 CSF3	0.113034	0.10195	0.072741	0.102288	0.071468	-0.0308	0.088778	
CTSB	0.115054	0.10193	0.072741	-0.04035	0.071408		0.000//0	0.098683964
CTSL	0.104649	0.07678	-0.04173	-0.04035			-0.06617	0.0331/1043
CISL	0.104049	0.07078	-0.041/3				-0.0001/	

CX3CR1	0 07252	0.0944	0.05060	0.05941	0.043399	0.05152	-0.04299	
CXCL2 CXCL5	-0.07253	-0.0844	-0.05969	-0.05841	-0.06559	-0.05153	-0.04755	0.03806835
CXCL9						-0.03978		
CXCR3	0.069483	0.048237			0.037495			0.085780591
CXCR5	0.125108	0.091302	0.039747	0.064412			0.053469	0.056036
CXCR6	0.056839	0.055155	0.063929			0.05574.4	0.044044	0.057363906
DES EDN1	-0.04828		-0.04554			0.055714	0.041941	
EOMES	0.04828	0.076171	-0.04554	0.045833				0.050475746
FABP4	0.004200	0.070171		-0.03939				0.050475740
FBLN1	-0.07795	-0.06019	-0.0729	-0.04823			-0.06675	-0.099788911
FCGR2A		0.044455						
FCGR3B	0.040975	0.037913						0.072317848
FKBP11	0.063241	0.040355	0.056659					
FOLR2						-0.04681		
FOXI1	0.045565							
FOXN4						0.043416	0.043758	
FOXP3	0.039537		0.050424		0.048612		0.060758	0.056544832
	0.00074	0.070000	0.040201	0.00240		0.044150	0.045908	
FUT4 GATA2	0.08674	0.072236	0.040281	0.06246		0.044159 -0.04118		
GATAZ GJA5	0.042105	0.043181				-0.04118		
GNLY	0.049135	0.045101					0.039547	
GPR183	01010100						-0.05082	
GYPA		0.044047						
GZMK	0.162548	0.117448	0.066982	0.07485		0.102471	0.053519	0.121910499
HPGDS								-0.058750952
ICAM1							0.051938	
ICOSLG	0.094865	0.108561	0.059662	0.058779	0.06085		0.046443	0.048873673
IDO1		0.039485				0.037285		
IFITM3					0.004211			-0.0401819
IFNB1 IFNG		0.047643			0.064311 -0.03724			0.04148565
IFNG IFNGR1	-0.06606	-0.06479	-0.04459		-0.06533	-0.0605		-0.043583766
IFNGR2	0.00000	-0.04789	0.04433		0.00555	0.0005		0.041613098
IGKC	0.200164	0.207234	0.10137	0.08933	0.115094	0.106026	0.061718	0.065923338
IGLL5					0.045037			
IL10RB			0.04243		0.042023	0.043005		
IL17A	0.051116	0.052451					0.049536	
IL1A	0.061588	0.050096						
IL1B		0.038184					0.038756	
IL22	0.04000-						0.041126	0.037526937
IL27	0.040339				0.052045			
IL2RA	0.073001				0.053015		0.054686	

IL33 IL3RA			-0.03945				-0.03722 0.043497	
IL4 IL5 IL6	0.03914					0.065467	0.045197	-0.053733035
IL6R							0.044341	
IL6ST	-0.05528							
IL7R		-0.04831				-0.05257		
INMT	-0.12332	-0.06816	-0.19792				-0.06262	
ISG15	0.066814	0.038402	0.040259					
ITLN1	0.044288							0.049348458
JCHAIN	0.082298	0.052541			0.063171	0.058752		
KIT	-0.05272	-0.08017						-0.053323915
KLRC2					-0.04922		0.050395	
KLRD1							0.044409	0.044024242
KRT13 KRT14	0.040772							0.041034312
KRT14 KRT15	0.040772							
LST1	0.040743	0.140293	0.075228	0.097155	0.048409	0.150042	0.066195	0.117086543
LTF	0.170175	0.140295	0.075228	0.097133	0.048409	0.058064	0.000195	0.117080345
MGP					0.060665	0.000004		-0.047453011
MRC1					0.039171			0.017 100011
MSLN							-0.04002	-0.053807806
MUC5AC							-0.04623	
MUC5B	0.100919	0.037387	0.038258			0.037932		
MX1	0.037898							
NCAM1	0.129607	0.038924	0.070591	0.060254	0.040041			0.054425241
NRP1	-0.0381	-0.04668		-0.05298				
PAX5								0.053371989
PCSK1N								-0.076337283
PDCD1			0.037544					
PECAM1	-0.04893	-0.09513	-0.05137	-0.04777	-0.06127			
PLAC8	0.039513							
PLIN2	0 00 70 47	0.049445						
PPARG	0.037847						0 0 4 2 7 2	
PRF1 PRG4	-0.06815	-0.04201	-0.07122	-0.06506			-0.04373	
PKG4 PTN	-0.00813	-0.04201	-0.07122	-0.00500	-0.06056			
PTPRC			0.03705		0.00050			-0.05500837
RETN	0.066851	0.040041						0.03300037
S100A8	0.048937	01010012						
SEMA3A					0.059976			
SFTA2	0.090868							
SFTPA1	-0.07088	-0.05154						
SFTPA2							-0.04342	

SFTPC	-0.18456	-0.09881	-0.07617	-0.07591	-0.05003	-0.06539	-0.06338	-0.11238912
SLC18A2	0.059352							0.053280437
TGFB1		-0.0503						0.042625481
TMPRSS2						-0.04518		-0.07145939
TPPP3								-0.038857276
TPSAB1		-0.04459	-0.04399			0.038693	-0.04669	-0.291267486
TYROBP				-0.04596				